# Paper 1 work steps

*Claude Code session — last active 2026-10-06*


---

## @"C:\Users\nissa\Downloads\Immediate work for Paper 1.docx"

@"C:\Users\nissa\Downloads\Immediate work for Paper 1.docx"
so this is what..now my mentor said to continue sith...lets do it step by step...1st explain me clearly what we have to do in each step..then i will say to do it...then next step like that


<sub>ran — Bash: Extract text from the mentor's Word document · Bash: Extract raw text from the docx XML · Bash: Extract raw text from the docx XML with UTF-8 output · Bash: List repo files and find the relevant data files · Bash: Inspect README and progression/stage file headers</sub>

I've read the mentor's document. Now I'm pulling quick counts from your data so the plan uses real numbers.


<sub>ran — Bash: Count genes per group and check installed libraries</sub>

I've read the mentor's document and checked it against your data. There are **4 tasks**. Here's what each one asks for, in plain terms, with your real numbers.

---

## Task 1: Split the 4,692 genes into three groups

**What we have:** Each progression gene has a fibrosis score (ρ, how strongly it rises or falls with F0→F4) and/or an inflammation score (ρ, how strongly it tracks control→NAFL→NASH). Your file already labels the groups:

| Group | Genes |
|---|---|
| Fibrosis-only | 1,953 |
| Inflammation-only | 1,047 |
| Shared (both) | 1,692 |

**What we do:**
1. Count each group and give its percentage of 4,692.
2. Split each group into **positive** (expression goes up with disease) and **negative** (goes down).
3. For the 1,692 shared genes, plot fibrosis ρ against inflammation ρ, one dot per gene. Then compute a Spearman correlation between the two scores. This tells us whether genes that rise with fibrosis also rise with inflammation.
4. List the top 20 genes that rise most with fibrosis and the top 20 that fall most.

**Outputs:** a summary table, a Venn/UpSet plot, the scatter plot, and the top-20 table.
**Difficulty:** easy. It all comes from one file you already have.

---

## Task 2: How genes change from F0 to F4 (the mentor's top priority)

**What we have:** For every gene, `genes_by_fibrosis_stage.csv` gives its average expression at each stage (F0, F1, F2, F3, F4). It's based on 668 staged samples.

**What we do:**
1. Take the 3,645 fibrosis-associated genes (fibrosis-only plus shared). Each gene becomes a 5-point "shape" across the stages.
2. Let the computer **cluster** genes with similar shapes. We don't sort them by hand.
3. Try 3 to 8 clusters (k = 3–8). Choose the best k using:
   - **silhouette score**: how cleanly the clusters separate
   - **stability**: whether the clusters stay the same when we re-run on random subsets
4. Only after clustering, look at each cluster and name its shape, for example "gradual increase", "late increase" or "early decrease".

**Outputs:** a heatmap of all genes across F0–F4, one trajectory plot per cluster, gene counts per cluster, a CSV (`Gene | F0 | F1 | F2 | F3 | F4 | Cluster`), and the most typical genes in each cluster.

---

## Task 3: Where does the biggest jump happen?

**Question:** Which transition shows the largest molecular change: F0→F1, F1→F2, F2→F3 or F3→F4?

**What we do:**
1. For each gene, compute the change between neighbouring stages (Δ = stage mean at F(k+1) minus stage mean at F(k)).
2. The mentor says not to rely on averages alone, so we also run **real statistical tests on individual patients' data**. For each gene and each transition, we compare the samples at one stage with the samples at the next (for example a Mann-Whitney test), then correct for multiple testing. Your raw per-sample expression files are in `data/interim/`, so this is possible.
3. One detail: in GSE193066, 58 patients were biopsied twice. We have to count each patient once so they aren't double-counted.
4. Count how many genes change substantially at each transition. That shows where the big shift happens.

**Outputs:** the number of changing genes per transition, distributions of Δ, the top increasing and decreasing genes per transition, and one figure comparing all four transitions.

---

## Task 4: Pathway enrichment for each group

**Question:** What biology do these gene groups represent, such as collagen/ECM, immune response or lipid metabolism?

**What we do:**
1. Run enrichment **separately** for each group rather than on all genes at once:
   - fibrosis-only positive and negative
   - inflammation-only positive and negative
   - shared positive and negative
   - each important trajectory cluster from Task 2
2. Use four databases: GO Biological Process, KEGG, Reactome and MSigDB Hallmark.
3. Keep results with FDR < 0.05, and record the gene counts and which genes drive each pathway.
4. **Background:** compare against the ~14,794 genes that were tested in our analysis, not all ~20,000 human genes. Using all human genes would make results look more significant than they are, which is why the mentor stresses it.

**Outputs:** one CSV per enrichment, the top pathways per group, dot plots, and one combined heatmap comparing the groups.
**Setup needed:** I'll install `gseapy`, a Python enrichment package. It isn't installed yet.

---

### Order
Task 1 → Task 2 → Task 3 → Task 4. Task 4 needs the clusters from Task 2, so it goes last.

Two small notes:
- A couple of formulas in the Word file didn't come through when I extracted the text: the scatter-plot axes in Task 1 and the Δ formula in Task 3. I filled them in with the obvious meaning: fibrosis ρ vs inflammation ρ, and the difference between neighbouring stage means. Tell me if your mentor meant something else.
- I'll put all outputs in a new folder, `data/paper1/`, with a subfolder per task.

Say **"do Task 1"** when you're ready.


---

## not like thois 1st only step 1 then sgtep 2 like that

not like thois 1st only step 1 then sgtep 2 like that

Got it, one step at a time. Here's **Task 1 only**.

## Task 1: Divide the 4,692 genes into progression groups

**Background:** Each of your 4,692 progression genes was tested two ways:
- **Fibrosis**: does its expression change as fibrosis goes from F0 to F4? The answer is a number called **fibrosis ρ** (rho), between -1 and +1.
- **Inflammation**: does it change from healthy → NAFL → NASH? That gives **inflammation ρ**.

A positive ρ means the gene goes **up** as disease gets worse. A negative ρ means it goes **down**.

### What we'll do

**Part A: make three groups**

| Group | Meaning | Genes |
|---|---|---|
| Fibrosis-only | significant for fibrosis, not inflammation | 1,953 |
| Inflammation-only | significant for inflammation, not fibrosis | 1,047 |
| Shared | significant for both | 1,692 |

We'll show each group's count and its percentage of 4,692.

**Part B: split each group into up and down**
- Fibrosis-only → positive (goes up) and negative (goes down)
- Inflammation-only → positive and negative
- Shared → split the same way. A shared gene could go up for fibrosis but down for inflammation, so we'll count those mixed cases too.

**Part C: a Venn/UpSet plot**
One picture showing how the three groups overlap.

**Part D: a scatter plot for the 1,692 shared genes**
- The X-axis is fibrosis ρ and the Y-axis is inflammation ρ. Each dot is one gene.
- Then we compute a **Spearman correlation** between the two scores. If it's high, genes that rise with fibrosis also rise with inflammation, meaning both processes share the same molecular program.

**Part E: a top-20 table**
- The 20 genes that go **up** most strongly with fibrosis
- The 20 genes that go **down** most strongly with fibrosis

### Files you'll get (in `data/paper1/task1/`)
1. `task1_summary.csv`: counts and percentages
2. `task1_venn.png`: the overlap plot
3. `task1_shared_rho_scatter.png`: the scatter plot, with the correlation printed on it
4. `task1_top20_fibrosis_genes.csv`: the top 20 up and top 20 down

Everything comes from one file you already have, so it's quick.

Say **"do step 1"** when you're ready.


---

## do it

do it


<sub>ran — Bash: Check for Venn/UpSet plotting libraries · Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task1_groups.py · Bash: Run the Task 1 grouping script · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\data\paper1\task1\task1_shared_rho_scatter.png · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\data\paper1\task1\task1_venn.png · Bash: Show the one discordant shared gene · Bash: Compute correlation within up and down shared genes separately</sub>

Step 1 is done. All 4 files are in `data/paper1/task1/`.

## What we found

**1. The three groups (out of 4,692 genes)**

| Group | Genes | % of all | Up | Down |
|---|---|---|---|---|
| Fibrosis-only | 1,953 | 41.6% | 1,301 (67%) | 652 (33%) |
| Inflammation-only | 1,047 | 22.3% | 597 (57%) | 450 (43%) |
| Shared | 1,692 | 36.1% | 1,335 up in both | 356 down in both |

- More genes go **up** with disease than down in every group.
- Shared genes almost always move the **same way** in fibrosis and inflammation. Only one gene goes against that: **GPD1**, which goes down with fibrosis but up with inflammation.

**2. Scatter plot (shared genes)**
- Fibrosis ρ and inflammation ρ correlate strongly: **Spearman ρ = 0.725** (p ≈ 10⁻²⁷⁶).
- **Caution:** part of that 0.725 comes from the dots forming two separate clouds, an "up" group and a "down" group. If we look inside each cloud on its own, the correlation is lower: **0.45** for up genes and **0.35** for down genes. Both are still significant. I'd report both numbers, so a reviewer can't say the correlation is inflated.

**3. Top 20 fibrosis genes**
- **Most increased:** NALCN, STMN2, LAMC3, GABRE, PLPP4, NFASC, CCL20, DTNA, IL32, THBS2, FBLN5, ADAMTSL2, THY1, ITGBL1, CAPN2, SPATA21, LOXL4, CXCL8, CXCL1, LOXL1
- **Most decreased:** SLC16A10, KCNN2, COBLL1, SORD, CYP2C19, LPA, ACADSB, PPP1R1A, SLC38A4, HAAO, ABCC9, DNAJC12, ASXL3, DCAF6, HECTD1, NCAM2, ANXA10, EGFLAM, CLEC4M, OAT

The increased list looks biologically right: scar-tissue builders (LOXL1, LOXL4, THBS2, FBLN5), activated scar-forming cells (THY1) and inflammation signals (CXCL8, CXCL1, CCL20, IL32). The decreased list is mostly normal liver metabolism genes (CYP2C19, SORD, ACADSB, OAT), which fall as the liver gets damaged.

## Files
- [task1_summary.csv](data/paper1/task1/task1_summary.csv)
- [task1_venn.png](data/paper1/task1/task1_venn.png)
- [task1_shared_rho_scatter.png](data/paper1/task1/task1_shared_rho_scatter.png)
- [task1_top20_fibrosis_genes.csv](data/paper1/task1/task1_top20_fibrosis_genes.csv)
- The code is in [paper1_task1_groups.py](paper1_task1_groups.py), so it can be re-run.

The Venn shows two circles (fibrosis vs inflammation). I drew it myself because the Venn/UpSet plotting packages aren't installed.

Should I add the 0.45 and 0.35 numbers to the summary file and the plot? When you're ready, say **"explain step 2"** and I'll walk you through Task 2 before doing anything.


---

## what u do is create a folder for it inside that create task1 folder then add these files i

what u do is create a folder for it inside that create task1 folder then add these files in thbta..so i can send the folder

I'll make one top-level folder you can send, put Task 1 in its own subfolder, and point the script there so the files only exist in one place.


<sub>ran — Bash: Move Task 1 outputs into a shareable folder and update script path</sub>

Now a short README so your mentor knows what each file is:


<sub>ran — Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task1\README.txt</sub>

Task 1 is now in its own folder, ready to send. I moved the files out of `data/paper1/` so there's only one copy.

```
liver_kg/
└── Paper1_Results/
    └── Task1/
        ├── README.txt                       ← what each file is + key numbers
        ├── task1_summary.csv
        ├── task1_venn.png
        ├── task1_shared_rho_scatter.png
        └── task1_top20_fibrosis_genes.csv
```

- **New README:** it lists each file and the key numbers, so your mentor doesn't need you there to explain. It also has the 0.45 and 0.35 correlations from inside the up and down groups.
- **Re-running:** I changed the script to save into this folder, so running it again overwrites these files instead of making a second set elsewhere.
- **Later tasks:** they'll go into `Task2`, `Task3` and `Task4` next to it.

You can send the `Task1` folder now, or wait and send all of `Paper1_Results` at the end.

When you're ready, say **"explain step 2"**.


---

## explain step 2

explain step 2


<sub>ran — Bash: Check how many samples are in each fibrosis stage</sub>

## Task 2: How genes change from F0 to F4

This is the step your mentor marked **highest priority**.

### The question
As the liver scars from F0 (no fibrosis) to F4 (cirrhosis), genes don't all change the same way. Some rise steadily, some stay flat and then jump at the end, some drop early. We want to **find these patterns from the data** and see which genes follow each one.

### What we start with
- **Genes:** the **3,645 fibrosis-associated genes** from Task 1 (1,953 fibrosis-only plus 1,692 shared). Inflammation-only genes are left out because they weren't significant for fibrosis.
- **Values:** for each gene, its average expression at F0, F1, F2, F3 and F4, taken from `genes_by_fibrosis_stage.csv`.
- **Samples behind each stage** (668 total):

| F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|
| 152 | 168 | 186 | 127 | **35** |

  F4 has far fewer samples, so its averages will be noisier. We'll keep that in mind when reading the results.

### Steps

**Step 2.1: Make each gene's pattern comparable by shape**
Gene A might go from 0.1 to 0.3 and gene B from -1 to +1. Both are "gradual increase", just at different sizes. To group genes by **shape, not size**, we rescale each gene's 5 values to mean 0 and spread 1. After that, the computer only sees the shape of the curve.

**Step 2.2: Cluster the genes**
We use **k-means clustering**, which puts genes with similar curves into the same group. We don't tell it what the groups should be. The data decides.

**Step 2.3: Pick the number of clusters (k)**
We try **k = 3, 4, 5, 6, 7 and 8**, and judge each one two ways:
- **Silhouette score:** are genes much closer to their own cluster than to other clusters? Higher is better.
- **Stability:** re-run the clustering many times on random 80% subsets of the genes. If the same clusters keep appearing, they're real and not chance. We measure this with the **Adjusted Rand Index** (1 means perfectly stable).

We pick the k that scores well on both, and show your mentor the scores for every k so the choice is transparent.

**Step 2.4: Name the clusters, but only after clustering**
Once clusters exist, we look at each one's average curve and describe it, for example "gradual increase", "late increase (jump at F3→F4)" or "early decrease". The mentor was explicit: **don't sort genes into these categories by hand first**.

**Step 2.5: Find the most typical genes in each cluster**
For every cluster, list the genes whose curves are **closest to the cluster's average curve**. These are its best examples, useful in the paper ("Cluster 3, late increase, includes COL1A1, LOXL2, …").

### Files you'll get (in `Paper1_Results/Task2/`)
1. **Heatmap:** all 3,645 genes (rows) × F0–F4 (columns), sorted by cluster, so the patterns are visible at a glance
2. **Trajectory plots:** one small plot per cluster, showing every gene's line in light grey and the cluster average in bold
3. **Cluster sizes:** how many genes are in each cluster
4. **Main CSV:** `Gene | F0 | F1 | F2 | F3 | F4 | Cluster`
5. **Top representative genes** for each cluster
6. **Choosing-k plot:** silhouette and stability for k = 3–8, which justifies the k we chose
7. **README.txt**, like Task 1

### One limitation to know
Clustering 5 averaged points per gene is the standard approach for this kind of analysis, but it doesn't use the individual patients. That's fine for Task 2. The patient-level statistics come in Task 3, which checks whether these changes are significant.

Say **"do step 2"** when you're ready.


---

## ok do it

ok do it

I'll start by testing k = 3–8, then choose k from those scores before building the rest.


<sub>ran — Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Bash: Evaluate cluster numbers k=3 to 8</sub>

k = 3 scores best on both measures, and k = 3–6 are all stable (ARI > 0.94). Before choosing, I'll check whether k = 3 merges patterns the mentor wants kept apart, such as early vs late.


<sub>Bash: Show average cluster curves for k=3 to 6 · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Bash: Run full Task 2 clustering and plotting · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task2\task2_cluster_trajectories.png</sub>


---

## [Image: original 3789x2009, displayed at 2000x1060. Multiply coordinates by 1.89 to map to

[Image: original 3789x2009, displayed at 2000x1060. Multiply coordinates by 1.89 to map to original image.]


<sub>Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task2\task2_heatmap.png · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task2\task2_choosing_k.png · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task2\task2_cluster_means.png</sub>


---

## [Image: original 2971x1191, displayed at 2000x802. Multiply coordinates by 1.49 to map to 

[Image: original 2971x1191, displayed at 2000x802. Multiply coordinates by 1.49 to map to original image.]


---

## [Image: original 1722x2504, displayed at 1375x2000. Multiply coordinates by 1.25 to map to

[Image: original 1722x2504, displayed at 1375x2000. Multiply coordinates by 1.25 to map to original image.]


<sub>ran — Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task2\README.txt</sub>

Step 2 is done. Everything is in `Paper1_Results/Task2/`, ready to send like Task 1.

## What we found

The computer found **5 patterns** in the 3,645 fibrosis genes:

| Cluster | Pattern | Genes | Example genes |
|---|---|---|---|
| **C1** | Early increase: jumps at F0→F1, then keeps rising | 927 (25%) | COL5A2, NOD2, DOCK8 |
| **C2** | Late increase: flat until F2, then shoots up at F3→F4 | 1,514 (42%) | GDF15, ANXA1, LRRC32 |
| **C3** | Rise then fall: peaks at F3, drops at F4 | 197 (5%) | CDC20, TOP2A, ORC1, CDC25A |
| **C4** | Mid decrease: drops at F1→F2 | 309 (8%) | F10, SERPINC1, FERMT2 |
| **C5** | Late decrease: biggest drop at F3→F4 | 698 (19%) | SLC2A2, ADH6, PDK4, SLC27A2 |

### What it means
- **Most changes happen late.** The largest group (C2) and the biggest down group (C5) both change most at **F3→F4**, the move into cirrhosis.
- **Some genes change early.** C1 already rises at F0→F1, so it could hold early-warning markers.
- **C5 is normal liver function being lost.** These are sugar and fat metabolism genes (SLC2A2, ADH6, PDK4) that fade as the liver fails.
- **C3 is interesting but needs care.** It's full of cell-division genes (TOP2A, CDC20), suggesting cell proliferation peaks at F3. But its drop at F4 rests on only **35 F4 samples**. Task 3's patient-level tests will show whether that drop is real.

### How k = 5 was chosen
- k = 3 had the best silhouette score, but it merged genuinely different shapes, such as the two decrease patterns.
- Rule used: **the largest k with stability ARI ≥ 0.95**. That gives k = 5 (ARI 0.96).
- The `task2_choosing_k.png` plot shows the scores for every k, so your mentor can see the choice is justified.

## Files
- [task2_gene_clusters.csv](Paper1_Results/Task2/task2_gene_clusters.csv): Gene | F0–F4 | Cluster, the main table
- [task2_heatmap.png](Paper1_Results/Task2/task2_heatmap.png)
- [task2_cluster_trajectories.png](Paper1_Results/Task2/task2_cluster_trajectories.png): one plot per cluster
- [task2_cluster_means.png](Paper1_Results/Task2/task2_cluster_means.png): all 5 clusters on one plot
- [task2_cluster_sizes.csv](Paper1_Results/Task2/task2_cluster_sizes.csv)
- [task2_representative_genes.csv](Paper1_Results/Task2/task2_representative_genes.csv): top 15 per cluster
- [task2_choosing_k.png](Paper1_Results/Task2/task2_choosing_k.png) and its `.csv`: the justification for k
- [README.txt](Paper1_Results/Task2/README.txt): the method and results in plain text
- The code is in [paper1_task2_trajectories.py](paper1_task2_trajectories.py).

When you're ready, say **"explain step 3"**.


---

## ok explain step 3

ok explain step 3

Before I explain, I'm checking what patient-level data we have, so the plan matches what's actually possible.


<sub>ran — Bash: Check sample-level expression data and stage counts per study</sub>

## Task 3: Where does the biggest change happen?

### The question
Fibrosis has four steps: **F0→F1, F1→F2, F2→F3 and F3→F4**. At which step do the most genes change, and by the most? That tells us when the liver's biology really shifts.

Task 2 hinted at the answer, since most clusters jump at F3→F4. But Task 2 only used **averages**. Your mentor wants this backed by **real statistics on individual patients**.

### What we have
Expression for every gene in every patient sample: 668 staged samples from 610 patients across 5 studies.

### Steps

**Step 3.1: The simple version (difference of averages)**
For each of the 3,645 fibrosis genes, compute the change at each step, for example Δ(F0→F1) = average at F1 minus average at F0. That gives 4 Δ values per gene, which we plot as distributions.

**Step 3.2: The proper version (patient-level statistics)**
For each gene and each step, compare the patients in one stage with the patients in the next and ask whether the difference is real or just noise. Two things need careful handling:

- **Problem 1: the studies don't all have every stage.** For example, GSE193066 has 71 F2 samples but only 1 at F4. Expression was standardised within each study, so comparing stages across studies can create false differences.
  → **Fix:** the test includes **which study** each sample came from, so it only compares stages *within the same study*. This is a regression: `expression ~ stage + study`.

- **Problem 2: some patients were biopsied twice** (58 in GSE193066).
  → **Fix:** if one patient has two samples in the same stage, we average them so each patient counts **once**.

Then we correct for testing thousands of genes (**BH-FDR**).

**Step 3.3: Define "substantially changing"**
A gene counts as substantially changing at a step if:
- it is statistically significant (FDR < 0.05), **and**
- the change is meaningfully large (|Δ| ≥ 0.2 standard deviations), so tiny but "significant" changes are ignored.

Then we count how many genes pass at each step.

**Step 3.4: Be fair about sample size**
F4 has only **35 samples**, against 127–186 for the other stages. Fewer samples make significance harder to reach, so F3→F4 might show fewer significant genes **even if the change is the largest**. So we don't judge by counts alone. We also compare **effect sizes** (how big the changes are), and say this clearly in the README.

### Files you'll get (in `Paper1_Results/Task3/`)
1. **Count table:** number of substantially changing genes per step, split into up and down
2. **Δ distributions:** a plot showing the spread of changes at each of the 4 steps
3. **Top genes per step:** the 20 most increasing and 20 most decreasing genes at each step
4. **Comparison figure:** all 4 steps side by side (gene counts plus effect sizes), which answers "where is the major change?"
5. **Full results CSV:** every gene × every step, with Δ, p-value and FDR
6. **README.txt**, like before

### Bonus check
At the end, we look at whether **C3** (the cell-division genes that seemed to drop at F4) really drops significantly at F3→F4. That answers the open question from Task 2.

Say **"do step 3"** when you're ready.


---

## ok do it

ok do it


<sub>ran — Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\export_for_mentor.py · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\export_for_mentor.py · Bash: Check expression files and repeat-biopsy stage patterns · Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task3_transitions.py · Bash: Run Task 3 transition analysis</sub>

statsmodels isn't installed, so I'll use scipy's built-in BH-FDR instead. It gives the same result.


<sub>ran — Bash: Switch to scipy BH-FDR and rerun Task 3 · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task3_transitions.py · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task3_transitions.py · Bash: Rerun Task 3 with study-balanced power matching · Bash: Show transition summary table · Bash: Show transition summary table with UTF-8 output</sub>

The summary file hasn't changed, so the last run must have failed quietly. Re-running with the errors visible:


<sub>ran — Bash: Rerun Task 3 and show the output tail</sub>

One study has zero patients at a stage in one of the pools. I'll count zeros properly, and leave a study out of the matched design whenever it can't supply a patient at every stage.


<sub>Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task3_transitions.py · Bash: Rerun Task 3 with fixed power-matched design · Bash: Locate the power-matched panel code · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task3_transitions.py · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task3_transitions.py · Bash: Rerun Task 3 to regenerate figures · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task3\task3_transition_comparison.png</sub>


---

## [Image: original 4470x1311, displayed at 2000x587. Multiply coordinates by 2.23 to map to 

[Image: original 4470x1311, displayed at 2000x587. Multiply coordinates by 2.23 to map to original image.]


<sub>Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task3\task3_delta_distributions.png</sub>


---

## [Image: original 3570x1337, displayed at 2000x749. Multiply coordinates by 1.78 to map to 

[Image: original 3570x1337, displayed at 2000x749. Multiply coordinates by 1.78 to map to original image.]


<sub>ran — Bash: Show top genes per transition · Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task3\README.txt · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task2\README.txt</sub>

Step 3 is done. Everything is in `Paper1_Results/Task3/`.

## The answer: the biggest molecular change is at F3→F4 (into cirrhosis)

| | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Patients compared | 152 / 166 | 160 / 165 | 165 / 109 | 118 / **34** |
| Substantially changing genes | 1,165 | 1,175 | 1,117 | 936 |
| Typical size of change (median \|Δ\|) | 0.19 | 0.19 | 0.22 | **0.38** |
| **Fair comparison** (same 30 patients per stage) | 0 | 0 | 2 | **311** |

### How to read it
- **At first glance** all four steps look similar, with about 900–1,200 genes each. But F3→F4 has only **34 F4 patients**, so it's much harder for a change to reach significance there.
- **Fair comparison:** when every step gets the same number of patients from the same studies, F3→F4 wins easily. Its median is **311 genes**, against **0–2** for the other steps.
- **Effect size**, which doesn't depend on sample size, agrees: changes at F3→F4 are about **twice as large** as at any earlier step.
- **Conclusion:** earlier steps have many **small** changes. The move into cirrhosis has **big** changes.

### Other findings
- **F0→F1 is almost only increases** (1,135 up vs 30 down). Genes switching off mostly starts at **F1→F2** (528 down).
- **Top genes make biological sense:**
  - **F1→F2 up:** COL1A1 (collagen), CCL20 and ITGAX (immune cells move in)
  - **F2→F3 up:** LOXL1, FBLN5 and MOXD1 (scar tissue matures)
  - **F2→F3 down:** STAB2, CLEC4M, FCN2 and KDR. These are markers of the liver's specialised blood-vessel cells, so losing them is a known step in fibrosis, called "capillarization".
  - **F3→F4 up:** MMP7, KRT23 and PLVAP. **Down:** CYP2E1 and SLC22A1, as normal liver metabolism is lost.

### Question from Task 2 answered
The **C3 cluster's drop at F4 is not real.** At the patient level, 0 of its 197 genes drop significantly at F3→F4. C3 is better described as "early rise, then plateau". I added this correction to the Task 2 README so the two tasks don't contradict each other.

## Files
- [task3_transition_comparison.png](Paper1_Results/Task3/task3_transition_comparison.png): the main figure, all 4 steps compared
- [task3_delta_distributions.png](Paper1_Results/Task3/task3_delta_distributions.png): spread of changes at each step
- [task3_transition_summary.csv](Paper1_Results/Task3/task3_transition_summary.csv): the table above
- [task3_top_genes_per_transition.csv](Paper1_Results/Task3/task3_top_genes_per_transition.csv): top 20 up and top 20 down per step
- [task3_all_genes_all_transitions.csv](Paper1_Results/Task3/task3_all_genes_all_transitions.csv): every gene × step, with full statistics
- [task3_cluster_by_transition.csv](Paper1_Results/Task3/task3_cluster_by_transition.csv): Task 2 clusters checked at patient level
- [README.txt](Paper1_Results/Task3/README.txt)
- The code is in [paper1_task3_transitions.py](paper1_task3_transitions.py).

When you're ready, say **"explain step 4"**. That's the pathway enrichment, the last task.


---

## upto now whatever we did...everythimng is correct only right

upto now whatever we did...everythimng is correct only right

I'll check this properly instead of just saying yes. The biggest open question is whether Task 2 is affected by the same study-mix problem we fixed in Task 3, so I'm testing that now.


<sub>ran — Bash: Check whether Task 2 clusters survive study adjustment</sub>

Mostly yes. The calculations are correct and the main conclusions hold. But "correct" isn't the same as "nothing a reviewer could question", so here's an honest review.

## Checked and solid
- **Task 1:** the counts, percentages, scatter plot and top-20 lists come straight from your data. Nothing to question.
- **Task 2 clusters are robust.** I just ran the check above. Task 2 used plain stage averages, which mix studies with different stage proportions (the problem we fixed in Task 3). So I redid the clustering on study-adjusted values:
  - Each gene's curve barely changes (median correlation **0.998**).
  - The clusters mostly agree (ARI **0.84**). Each cluster maps onto the same pattern; only genes on the borderline between C1 and C2 move.
  - So the 5 patterns are real, not caused by study mix.
- **Task 3** handles the tricky parts: study differences, repeat biopsies and the small F4 group.

## Things to tell your mentor (limitations, not mistakes)
1. **Circularity in Task 3.** These genes were *selected* because they track fibrosis in this same data, so the significance counts in Task 3 are inflated. **Comparing the four steps is still fair**, because all of them use the same genes, and that comparison is the actual question. But don't read "1,165 significant genes" as an independent discovery.
2. **Choosing k = 5.** Silhouette alone favoured k = 3. I set the rule "largest k with stability ≥ 0.95" after looking at the curves, and I should be upfront about that. The choosing-k plot shows all the numbers, so your mentor can judge.
3. **Stability was tested by resampling genes, not patients.** Resampling patients would be a stronger test. It can be added if your mentor wants it.
4. **The C3 name is out of date in the CSVs.** Task 3 showed C3 doesn't really drop at F4. I fixed the README, but the Task 2 files still label it "Rise to F3, then reverse". Better: **"Early rise, then plateau"**.
5. **Arbitrary thresholds.** The 0.2 SD cutoff for "substantial" is a reasonable convention, not a rule. Results with other cutoffs could be shown if needed.
6. **F4 is small (34 patients).** Everything about F3→F4 rests on fewer patients. The power-matched check deals with this, but it's still worth stating.

## Should I fix anything before Step 4?
- **Item 4:** I'd rename C3 in the Task 2 files now. It takes a minute and keeps your files consistent.
- **Item 3:** optional. I can add a patient-resampling stability check to Task 2.
- **Items 1, 2, 5 and 6:** these just need stating, and I can add them to the READMEs.

Should I do item 4, and item 3 too? Or move straight on to explaining Step 4?


---

## do it

do it

I'll do both, plus add the limitation notes to the READMEs. I'll also move the study-adjustment check I just ran into the Task 2 script, so it's saved with the results instead of living in a temporary file.


<sub>ran — Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py</sub>

Now adding the patient-bootstrap stability to the k loop, plus the C3 rename and the study-adjustment check:


<sub>ran — Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py</sub>

Now the study-adjustment check at the end of the script:


<sub>ran — Bash: Show the end of the Task 2 script · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Bash: Rerun Task 2 with robustness checks and C3 rename · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Bash: Add imports/column and rerun Task 2 bootstrap analysis · Bash: Locate representative-gene selection code · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task2_trajectories.py · Bash: Rerun Task 2 then Task 3 to propagate changes · Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task2\README.txt · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task3\README.txt · Bash: Update C3 wording in Task 3 README and list outputs</sub>

I've made both fixes and re-run Tasks 2 and 3. The new robustness check was worth doing: it showed a weakness that you should know about before sending.

## What changed

**1. C3 renamed.** It's now "Early rise, then plateau" everywhere: the CSVs, plots and READMEs of Tasks 2 and 3.

**2. Patient-level stability check added.** This tests whether the clusters hold up when we resample *patients*, which is harder to pass than resampling genes.
- **The 5 patterns are real.** With resampled patients, the same 5 shapes come back every time (correlation 0.97–0.997). They are also not caused by the different stage mix in each study (adjusted curves correlate 0.998 with the originals).
- **Which cluster each gene is in is less certain.** Many genes switch between neighbouring clusters, mostly among the three increasing ones (C1, C2, C3), which differ only in *when* the gene rises. Each gene now has a **membership_confidence** score, the fraction of 100 resamples in which it stayed in its cluster:

| Cluster | Genes | High-confidence (≥ 0.8) |
|---|---|---|
| C1 Early increase | 927 | 47 |
| C2 Late increase | 1,514 | 841 |
| C3 Early rise, then plateau | 197 | 36 |
| C4 Mid decrease | 309 | 78 |
| C5 Late decrease | 698 | 423 |

**3. Representative genes are now picked from high-confidence genes.** This replaces the list I gave you in Step 2, and it reads as clearer biology:
- **C2:** CCN2 (CTGF, a classic fibrosis gene), KRT23, IER3
- **C3:** cell division (ANLN, ASPM, KIF20A, RRM2, TTK)
- **C5:** liver metabolism (SLC27A2, ADH6, PDK4)

**4. Limitations are now written in the READMEs.** These cover the circularity in Task 3, the k = 5 rule being set after looking at the curves, the 0.2 SD cutoff, and the small F4 group.

## What this means for your paper
- **Safe to say:** "We found five reproducible expression patterns across fibrosis stages, and the largest change happens at F3→F4."
- **Avoid saying:** "Gene X belongs to cluster 1", unless gene X has high confidence.

## Does it change Task 4?
A little. For the cluster enrichments, I'd run them on **all genes in each cluster**, then repeat them on **only the high-confidence genes** as a check. If both give the same pathways, the result is solid.

All files are updated in `Paper1_Results/`. Say **"explain step 4"** when you're ready.


---

## ok explain step 4

ok explain step 4

Before I explain, I'm quickly checking which gene sets we can test against, so the plan is accurate.


<sub>ran — Bash: Count background genes and check gseapy availability</sub>

## Task 4: Pathway enrichment (what biology each gene group represents)

### The question
So far we have **lists of genes**: up with fibrosis, down with inflammation, the late-increase cluster, and so on. A list of 1,300 gene names doesn't tell a reader much. Enrichment answers: **"Which biological processes are over-represented in this list?"** For example: "the fibrosis-up genes are full of collagen and scar-tissue genes" or "the late-decrease cluster is full of fat-metabolism genes".

### How enrichment works (simple version)
Take one pathway, for example "collagen formation", with 80 genes.
- In our list of 1,300 genes, suppose **25** are collagen-formation genes.
- By chance alone we'd expect about **7**.
- 25 is far more than 7, so the pathway is **enriched**. A statistical test (hypergeometric) gives the p-value.

### Steps

**Step 4.1: Build the gene groups, each one separately** (your mentor said don't put all 4,692 genes into one analysis)

| Group | Genes |
|---|---|
| Fibrosis-only, up | 1,301 |
| Fibrosis-only, down | 652 |
| Inflammation-only, up | 597 |
| Inflammation-only, down | 450 |
| Shared, up | 1,335 |
| Shared, down | 356 |
| Task 2 clusters C1–C5 | 927 / 1,514 / 197 / 309 / 698 |
| **Check:** C1–C5 high-confidence genes only | 47 / 841 / 36 / 78 / 423 |

That's 11 main groups plus 5 check groups.

**Step 4.2: Use four pathway databases**
- **GO Biological Process:** detailed processes ("collagen fibril organization")
- **KEGG:** classic pathways ("PPAR signaling")
- **Reactome:** detailed molecular pathways
- **MSigDB Hallmark:** 50 broad, well-curated themes ("Epithelial–mesenchymal transition", "Inflammatory response"). Easy for readers to interpret.

**Step 4.3: Use the correct background (your mentor's key point)**
- The "expected by chance" number depends on which genes we compare against.
- The default compares against all ~20,000 human genes. That's **wrong** here, because we only ever **tested 14,794 genes** (the ones measured in all studies).
- Genes we never tested had no chance to be in our lists. Including them makes everything look more enriched than it is.
- → We use the **14,794 tested genes as the background**. To do that, I'll run the test **locally on our own computer**, not through a website. Website tools often ignore custom backgrounds.

**Step 4.4: Filter and keep the details**
- Keep pathways with **FDR < 0.05** (BH-corrected).
- For each one, record: number of our genes in it, gene ratio (our genes ÷ pathway size), fold enrichment, and **which genes** drive it.

**Step 4.5: Check the clusters with high-confidence genes**
- From the Step 3 review: run each cluster's enrichment again using only its high-confidence genes.
- If the same pathways come out, the result is solid.

### Files you'll get (in `Paper1_Results/Task4/`)
1. **Separate CSVs** for each group × database
2. **Top pathways per group:** one summary table
3. **Dot plots:** one per group, showing the top pathways. Dot size = number of genes, colour = significance.
4. **Combined heatmap:** rows = biological processes, columns = groups (fibrosis-only / inflammation-only / shared / clusters). It shows at a glance which biology belongs to which group, and is likely the key figure for the paper.
5. **README.txt**

### What I need to install or download (asking your permission first)
- **gseapy** (Python enrichment package, version 1.3.1), via `pip install`
- **Gene set files** for the four databases, downloaded from the official Enrichr/MSigDB libraries. They're small text files of a few MB each.

### One thing to know
Some groups are small (for example C3's 36 high-confidence genes), so they may show few or no significant pathways. That's a real result, not an error.

Say **"do step 4"** to go ahead. That also gives permission for the install and downloads above.


---

## i didnt undersatnd what we have to do...tell me in simple words clearly

i didnt undersatnd what we have to do...tell me in simple words clearly

Sure. Here it is in simple words.

## What we have now
Lists of gene **names**, for example "1,301 genes that go up with fibrosis". But a name like *LOXL1* or *CCN2* means nothing to most readers. Nobody can read 1,301 names and understand what's happening in the liver.

## What Step 4 does
It turns each gene list into **plain biology**.

Every gene has a known job, for example making scar tissue, fighting infection or burning fat. Genes with the same job are grouped into **pathways**. Scientists have already built databases of these pathways.

So for each of our lists, we ask:

> **"Which jobs show up in this list much more than by chance?"**

### Example
- We have **1,301** "fibrosis-up" genes.
- Suppose **25** of them are "scar-tissue" genes.
- If we'd picked 1,301 genes at random, we'd expect only about **7** scar-tissue genes.
- 25 is far more than 7, so **this list is about making scar tissue**.

We do this for every job in the database, and keep only the ones that are clearly real (FDR < 0.05).

## What we do, step by step
1. **Take each gene list separately:** fibrosis up, fibrosis down, inflammation up, inflammation down, shared up, shared down, and the 5 clusters from Task 2.
2. **Check each list against 4 pathway databases** (GO, KEGG, Reactome, Hallmark). These are just 4 different "dictionaries" of gene jobs.
3. **Compare fairly.** We compare only against the **14,794 genes we actually tested**, not all 20,000 human genes. This is the point your mentor stressed. Comparing against genes we never tested would make results look better than they are.
4. **Save the answer** for each list: which jobs came up, and which genes caused it.

## What you'll get
A clear story like this (made-up example):
- **Fibrosis-up genes →** scar tissue, collagen
- **Inflammation-up genes →** immune response
- **Late-decrease cluster →** normal liver metabolism being lost

Plus pictures (dot plots and one big summary heatmap) that show this at a glance. That summary heatmap will probably be a main figure in the paper.

## What I need from you
To do this, I need to **install one Python tool (gseapy)** and **download the 4 pathway databases**. They're small, free and official files.

Say **"do step 4"** and I'll start.


---

## do it

do it


<sub>ran — Bash: Install gseapy enrichment package · Bash: List available Enrichr gene set libraries</sub>

The Enrichr website is slow to respond. I'm checking whether it's reachable at all:


<sub>ran — Bash: Test connectivity to Enrichr and MSigDB servers · Bash: Download four MSigDB gene set files · Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task4_enrichment.py · Bash: Check gene set download progress</sub>

Hallmark and KEGG have finished downloading; GO and Reactome are still coming in slowly from the server. The analysis script is written and ready. I'll run it as soon as the downloads finish. You'll be notified automatically, so you don't need to do anything.


<sub>ran — Bash: Show download results · Bash: Resume incomplete GO and Reactome downloads</sub>

While those finish, I'll test the script on the two complete databases (Hallmark and KEGG) to catch any bugs early. Its output goes to a scratch folder so it doesn't mix with the real results.


<sub>ran — Bash: Test-run Task 4 on Hallmark and KEGG only · Bash: Test-run Task 4 on Hallmark and KEGG only · Bash: Show background size and p-value check · Bash: Check GO and Reactome download progress</sub>

The downloads are still running but making progress:
- **Reactome:** about 1,430 of roughly 1,700 pathways, nearly done
- **GO:** about 1,120 of roughly 7,600, the biggest file and the slowest

The Broad Institute server is slow today. As soon as both files are complete, I'll check they aren't cut off and then run the full analysis. You'll get the results then, with nothing for you to do in the meantime.


<sub>ran — Bash: Verify gene set files are complete against server sizes</sub>

All four files are complete. Their sizes match the server byte for byte, and they hold 7,608 GO, 186 KEGG, 1,736 Reactome and 50 Hallmark gene sets. Running the full analysis:


<sub>Bash: Run full Task 4 enrichment analysis · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task4\task4_heatmap_hallmark.png · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task4\dot_plots\dot_shared_up.png</sub>


---

## [Image: original 3581x3842, displayed at 1864x2000. Multiply coordinates by 1.92 to map to

[Image: original 3581x3842, displayed at 1864x2000. Multiply coordinates by 1.92 to map to original image.]


---

## [Image: original 2666x2725, displayed at 1957x2000. Multiply coordinates by 1.36 to map to

[Image: original 2666x2725, displayed at 1957x2000. Multiply coordinates by 1.36 to map to original image.]

Everything looks right. Writing the README now:


<sub>ran — Write: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task4\README.txt · Bash: List Task 4 outputs and total folder size</sub>

Step 4 is done, so **all 4 tasks in your mentor's document are now complete**. Everything is in `Paper1_Results/` (25 MB), ready to send.

## What Step 4 found (in simple words)

| Gene group | What the genes do |
|---|---|
| **Fibrosis-only, up** | Immune cells getting activated (T cells, myeloid cells), inflammation signals |
| **Fibrosis-only, down** | Normal liver jobs: processing fats, bile acids and drugs |
| **Inflammation-only** | Very little. Only a weak interferon (antiviral-type) signal |
| **Shared, up** | **Scar tissue:** collagen, extracellular matrix, EMT. This is the core fibrosis programme |
| **Shared, down** | Breaking down amino acids, bile acid metabolism, blood clotting factors |
| **C1 Early increase** | Immune activation, which starts **early** at F0→F1 |
| **C2 Late increase** | Scarring and TGF-β, which speeds up **late** at F3→F4 |
| **C3 Early rise, plateau** | **Cell division** (cells multiplying) |
| **C4 Mid decrease** | No clear theme |
| **C5 Late decrease** | Liver metabolism **failing** as cirrhosis develops |

### The story for your paper
Taken together, the 4 tasks tell one connected story:
> **Immune activation starts early (F0→F1) → cells multiply → scar tissue builds up and speeds up late → normal liver metabolism collapses at the step into cirrhosis (F3→F4).**

This fits Task 3, where the biggest change was at F3→F4.

## Checks I did
- **Correct background:** everything was compared against the **14,794 tested genes**, not all human genes, as your mentor asked. I checked one p-value by hand, and it matched the tool exactly.
- **High-confidence check:** for C2, C3 and C5, the same pathways come out when using only high-confidence genes, so those results are solid. C1 holds only partly, because it has just 47 core genes. C4 is too weak to say anything.

## Main files to look at first
- [task4_heatmap_hallmark.png](Paper1_Results/Task4/task4_heatmap_hallmark.png): **the key figure**, showing all groups side by side
- [dot_plots/](Paper1_Results/Task4/dot_plots/): one picture per group
- [task4_top_pathways_per_group.csv](Paper1_Results/Task4/task4_top_pathways_per_group.csv): top pathways, with the genes responsible
- `enrichment_tables/`: 64 separate CSVs, one per group × database, as your mentor asked
- [README.txt](Paper1_Results/Task4/README.txt): explains everything

The code is in [paper1_task4_enrichment.py](paper1_task4_enrichment.py). The downloaded pathway files are in `data/genesets/`.

You can now send the whole **`Paper1_Results`** folder to your mentor. Each task folder has its own README.


---

## did u do for all the 4 datasets?

did u do for all the 4 datasets?

Yes, if by "4 datasets" you mean the **4 pathway databases** (GO, KEGG, Reactome, Hallmark). Every group was tested against all 4:

| | GO_BP | KEGG | Reactome | Hallmark |
|---|---|---|---|---|
| Per-group CSV tables (16 groups each) | ✅ | ✅ | ✅ | ✅ |
| In the dot plots (top 5 from each) | ✅ | ✅ | ✅ | ✅ |
| Combined heatmap | ✅ | ❌ | ✅ | ✅ |

That's 16 groups × 4 databases = **64 enrichment tables**.

One gap: **KEGG had no combined heatmap**. I'm adding it now so all 4 are covered.


<sub>Bash: Locate heatmap calls in Task 4 script · Edit: C:\Users\nissa\OneDrive\Desktop\liver_kg\paper1_task4_enrichment.py · Bash: Rerun Task 4 with KEGG heatmap and update README · Read: C:\Users\nissa\OneDrive\Desktop\liver_kg\Paper1_Results\Task4\task4_heatmap_kegg.png</sub>


---

## [Image: original 3582x2750, displayed at 2000x1535. Multiply coordinates by 1.79 to map to

[Image: original 3582x2750, displayed at 2000x1535. Multiply coordinates by 1.79 to map to original image.]

Yes, all 4 pathway databases (GO, KEGG, Reactome and Hallmark) are now complete for every group, including a combined heatmap for each.

| Database | Per-group tables | Dot plots | Combined heatmap |
|---|---|---|---|
| GO Biological Process | ✅ 16 | ✅ | ✅ [task4_heatmap_go_bp.png](Paper1_Results/Task4/task4_heatmap_go_bp.png) |
| KEGG | ✅ 16 | ✅ | ✅ [task4_heatmap_kegg.png](Paper1_Results/Task4/task4_heatmap_kegg.png) **(just added)** |
| Reactome | ✅ 16 | ✅ | ✅ [task4_heatmap_reactome.png](Paper1_Results/Task4/task4_heatmap_reactome.png) |
| Hallmark | ✅ 16 | ✅ | ✅ [task4_heatmap_hallmark.png](Paper1_Results/Task4/task4_heatmap_hallmark.png) |

The new KEGG heatmap tells the same story as the others:
- **Up groups** show focal adhesion, ECM–receptor interaction, cytokines and Toll-like receptor signalling (scarring and inflammation).
- **C3** shows the cell cycle.
- **Down groups and C5** show fatty acid metabolism, peroxisome, drug metabolism (cytochrome P450) and amino-acid breakdown (liver metabolism lost).

I also added the KEGG heatmap to the README.

If by "datasets" you meant the **8 GEO studies** instead:
- **Tasks 1 and 4** use genes found across **all 8 studies**.
- **Tasks 2 and 3** use the **5 studies that recorded fibrosis stage**. The other 3 have no F0–F4 information, so they can't be used for stage analysis.


---

## still what are u doing?

still what are u doing?

I'm not running anything. All the work is complete.

Everything is saved in the **`Paper1_Results`** folder:

```
Paper1_Results/
├── Task1/   ✅ gene groups, Venn, scatter, top-20 genes
├── Task2/   ✅ 5 F0→F4 patterns, heatmap, trajectory plots
├── Task3/   ✅ biggest change is at F3→F4
└── Task4/   ✅ pathways for every group, all 4 databases
```

Each folder has a **README.txt** that explains its files, so your mentor can read them without you.

You can send the whole `Paper1_Results` folder to your mentor now.

If you want, I can also:
- write a **one-page summary** of all 4 tasks to send along with the folder, or
- **save all the code to git** so it's backed up.


---

## u are running this

u are running this


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\1.png]


<sub>ran — ToolSearch: select:TaskStop · TaskStop</sub>

You were right, and I was wrong to say nothing was running. That task was still open, and I've now stopped it.

It was a leftover from the start of Step 4. I'd asked the Enrichr website for its list of pathway databases, but the site was too slow to answer. I switched to downloading the databases from MSigDB instead and forgot to close this request. It was only waiting for a reply and never used or changed any results.

Nothing is running now, and all 4 tasks in `Paper1_Results` are complete.


---

## give me the folder to download

give me the folder to download


<sub>ran — PowerShell: Zip the Paper1_Results folder · SendUserFile</sub>

The download card above is **Paper1_Results.zip** (11.9 MB). It contains all 4 task folders, and each one has its own README.txt.

You can send this zip file straight to your mentor. A copy is also saved at `liver_kg/Paper1_Results.zip` if you need it later.


---

## how to download it

how to download it

The file is already on your computer, so you don't need to download it. There are two easy ways to get to it.

**Option 1: from this chat**
Click the **Paper1_Results.zip** file card in my previous message, then choose to open or save it.

**Option 2: from File Explorer**
1. Open **File Explorer** (the yellow folder icon on your taskbar).
2. Go to **Desktop → liver_kg**.
3. You'll see **Paper1_Results.zip** there.

Or paste this path into the File Explorer address bar:
```
C:\Users\nissa\OneDrive\Desktop\liver_kg
```

**To send it to your mentor:** attach `Paper1_Results.zip` to an email or WhatsApp message like any normal file. At 11.9 MB, it's small enough for email.

I can also open that folder in File Explorer for you, if that helps.


---

## i want to know how we are teeling that these genes are raising like that...tell me in simp

i want to know how we are teeling that these genes are raising like that...tell me in simple words


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\2.png]

Good question. Here's how we decide a gene is "rising" (positive) or "falling" (negative), in simple steps.

## Step 1: Measure the gene in every patient
Each patient had a liver biopsy, and we know two things about them:
- their **fibrosis stage** (F0, F1, F2, F3 or F4)
- how much of each gene their liver was making (**expression**)

## Step 2: Line patients up by stage and look at the trend
For one gene, sort all patients from F0 to F4 and ask: **as the stage goes up, does this gene go up or down?**

Here are two real genes from your data (average expression per stage):

| Gene | F0 | F1 | F2 | F3 | F4 | Trend |
|---|---|---|---|---|---|---|
| **FGR** | -0.42 | -0.05 | 0.20 | 0.21 | 0.28 | goes **up**, so **positive** |
| **GCLC** | 0.20 | 0.25 | -0.06 | -0.28 | -0.71 | goes **down**, so **negative** |

## Step 3: Turn the trend into one number (Spearman ρ)
We use a score called **Spearman correlation (ρ)**, which runs from **-1 to +1**:
- **ρ above 0** (positive): the higher the stage, the **higher** the gene
- **ρ below 0** (negative): the higher the stage, the **lower** the gene
- **ρ near 0:** no trend

FGR has ρ = **+0.28**, so it's positive. GCLC has ρ = **-0.30**, so it's negative.

## Step 4: Make sure it isn't luck
We only call a gene positive or negative if **both** of these hold:
1. **Every study agrees on the direction.** We calculated ρ separately in each study. If one study said "up" and another said "down", the gene was thrown out.
2. **It's statistically significant**, meaning there's less than a 5% chance it's a false result after checking thousands of genes (q < 0.05).

## Your table, explained
- **Fibrosis-only, positive (1,301):** rise as fibrosis gets worse
- **Fibrosis-only, negative (652):** fall as fibrosis gets worse
- **Inflammation-only:** the same idea, but the ladder is healthy → NAFL → NASH instead of F0 → F4
- **Shared, positive (1,335):** rise with **both** fibrosis and inflammation
- **Shared, negative (356):** fall with **both**
- **Discordant (1 gene, GPD1):** falls with fibrosis but rises with inflammation, so it goes against the pattern

## One important point
We are **not** following the same patient over time. We are comparing **different patients** at different stages. So "the gene rises" really means:
> **"Patients with more advanced fibrosis have higher levels of this gene."**

That's the standard way to describe this kind of study, and worth phrasing carefully in the paper.


---

## explain this clearly in simple words

explain this clearly in simple words


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\3.png]

This plot shows the **1,692 shared genes**, the ones linked to **both** fibrosis and inflammation.

## How to read it
**Each dot is one gene.** Every gene has two scores from before:
- **Left to right (X-axis):** the **fibrosis score**, showing whether the gene goes up or down from F0 to F4
- **Bottom to top (Y-axis):** the **inflammation score**, showing whether it goes up or down from healthy to NAFL to NASH

So a dot's position tells you how that gene behaves in **both** diseases at once.

## The four corners

```
              Inflammation UP
                    │
   Fibrosis DOWN    │    Fibrosis UP
   Inflammation UP  │    Inflammation UP
     (1 gene)       │    (1,335 genes)  ← big cloud
 ───────────────────┼───────────────────
   Fibrosis DOWN    │    Fibrosis UP
   Inflammation DOWN│    Inflammation DOWN
   (356 genes)      │    (0 genes)
   ← small cloud    │    empty
                    │
             Inflammation DOWN
```

- **Top-right (big cloud):** genes that go **up** in both diseases
- **Bottom-left (small cloud):** genes that go **down** in both diseases
- **Bottom-right:** empty. No gene goes up with fibrosis but down with inflammation.
- **Top-left:** a single lonely dot, **GPD1**, the one exception

## What it means
**Almost every gene moves the same way in fibrosis and inflammation.** If a gene rises with fibrosis, it also rises with inflammation, and the same goes for falling. This suggests fibrosis and inflammation share **one common gene program**, which makes sense, because inflammation is what drives fibrosis.

## The number at the top
**Spearman ρ = 0.725** measures how well the two scores agree:
- 1.0 would be perfect agreement
- 0 would be no connection
- **0.725 is strong agreement**

The p-value (2.9e-276) is extremely small, so this is definitely not chance.

## One honest warning
**Why is there an empty gap in the middle?** Genes with scores near 0 weren't significant, so they were left out of the list. That's why we see **two separate clouds** instead of one continuous cloud.

**Why does that matter?** The two clouds sitting far apart **pushes the 0.725 higher**. If we look inside each cloud on its own, the agreement is lower but still real:
- inside the up cloud: **0.45**
- inside the down cloud: **0.35**

So in the paper, the safe wording is:
> "Shared genes almost always change in the **same direction** in fibrosis and inflammation (1,691 of 1,692), and genes that change more with fibrosis also tend to change more with inflammation."

These extra numbers are also in the Task 1 README.


---

## calculate Spearman correlation between the two rho values. can u tell me how this is done 

calculate Spearman correlation between the two rho values. can u tell me how this is done in simple words


<sub>ran — Bash: Get example shared-gene rho values</sub>

Sure. I'll walk through it with **6 real genes** from your data. We did exactly the same thing for all 1,692 shared genes; the computer just did the counting.

## The idea in one line
> **Do the genes with the highest fibrosis scores also have the highest inflammation scores?**

## Step 1: Write down both scores for each gene

| Gene | Fibrosis ρ | Inflammation ρ |
|---|---|---|
| CYP2E1 | -0.270 | -0.361 |
| FGR | 0.282 | 0.377 |
| COL1A1 | 0.448 | 0.568 |
| TREM2 | 0.469 | 0.558 |
| LOXL1 | 0.497 | 0.428 |
| CCL20 | 0.526 | 0.551 |

## Step 2: Turn the scores into ranks (1 = lowest, 6 = highest)
Spearman doesn't use the actual numbers. It only uses the **order**, like ranking students in a class.

| Gene | Fibrosis rank | Inflammation rank |
|---|---|---|
| CYP2E1 | 1 | 1 |
| FGR | 2 | 2 |
| COL1A1 | 3 | **6** |
| TREM2 | 4 | 5 |
| LOXL1 | 5 | **3** |
| CCL20 | 6 | 4 |

## Step 3: See how different the two ranks are for each gene

| Gene | Difference (d) | d × d |
|---|---|---|
| CYP2E1 | 1 − 1 = 0 | 0 |
| FGR | 2 − 2 = 0 | 0 |
| COL1A1 | 3 − 6 = −3 | 9 |
| TREM2 | 4 − 5 = −1 | 1 |
| LOXL1 | 5 − 3 = 2 | 4 |
| CCL20 | 6 − 4 = 2 | 4 |
| | **Total** | **18** |

We square the differences (d × d) so negative and positive differences don't cancel out.

## Step 4: Put it into the formula

$$\rho = 1 - \frac{6 \times \text{total}}{n \times (n^2 - 1)}$$

Here n = 6 genes and the total = 18:

$$\rho = 1 - \frac{6 \times 18}{6 \times 35} = 1 - \frac{108}{210} = 1 - 0.51 = \mathbf{0.49}$$

## Step 5: Read the answer
- **ρ = +1:** the ranks match perfectly (the highest in fibrosis is also the highest in inflammation)
- **ρ = 0:** no connection between the two rankings
- **ρ = −1:** the ranks are exact opposites

For these 6 genes, **ρ = 0.49**: they mostly agree, but not perfectly (COL1A1 and LOXL1 swap places).

## For your real result
We did the same thing for **all 1,692 shared genes** and got:
> **ρ = 0.725**, which is strong agreement. Genes that change a lot with fibrosis usually also change a lot with inflammation.

The **p-value (2.9e-276)** tells us how likely it is to see this much agreement by pure chance. It's practically zero.

## Why Spearman instead of normal (Pearson) correlation?
- Spearman uses **ranks**, so a few extreme genes can't distort the result.
- It only asks "do they go up **together**?", not "do they go up in a perfectly straight line?"

That makes it the safer choice for this kind of data.


---

## how we picked these top 20 genes tell me clearly in simple words

how we picked these top 20 genes tell me clearly in simple words


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\4.png]


<sub>ran — Bash: Check top-20 q values and ladder mix</sub>

It's a simple ranking. Here's how it was done.

## Step 1: Start with all fibrosis genes
We took the **3,645 fibrosis-associated genes**: fibrosis-only (1,953) plus shared (1,692). Each one already had a **fibrosis score (ρ)** from before, which says how strongly the gene goes up or down from F0 to F4.

## Step 2: Sort them by fibrosis score
We lined up all 3,645 genes from **highest score to lowest**:

```
Highest ρ  →  NALCN  0.580    ← rises the most with fibrosis
              STMN2  0.574
              LAMC3  0.538
              ...
              (thousands of genes in the middle)
              ...
              COBLL1 -0.453
              KCNN2  -0.459
Lowest ρ   →  SLC16A10 -0.469 ← falls the most with fibrosis
```

## Step 3: Take the 20 at each end
- **Top 20 positive:** the 20 genes with the **highest** fibrosis scores, the strongest rising genes
- **Top 20 negative:** the 20 genes with the **lowest** fibrosis scores, the strongest falling genes

That's the whole method: **sort by fibrosis ρ, then take the top and bottom 20.**

## What the columns mean
| Column | Meaning |
|---|---|
| **rank** | position in the list (1 = strongest) |
| **symbol** | gene name |
| **fibrosis_rho** | fibrosis score, used for ranking |
| **fibrosis_q** | how sure we are it's real (smaller = more sure) |
| **inflammation_rho** | the gene's inflammation score, just for information |
| **ladder** | "both" = shared gene, "fibrosis_only" = fibrosis only |
| **direction** | positive = rises, negative = falls |

## ⚠️ One thing to watch in Excel
The **fibrosis_q** column looks like **1.6154774**, but that's **not** the real number. The column is too narrow, so Excel has cut it off. The real value is:
> **1.6 × 10⁻³⁷**, which is 0.000…00016 with 36 zeros after the decimal point

That's an extremely tiny number, meaning **we're extremely sure these genes are real**.

To see the full value, **double-click the line between the column letters** at the top of Excel, or widen the column.

## An interesting point
**34 of the 40** top genes are "both" (shared). The strongest fibrosis genes are mostly **also inflammation genes**, which fits the scatter plot: fibrosis and inflammation share the same core genes.

Sure. I'll go through it in 4 simple parts, using real numbers from your data.

## Part 1: Make each gene's "pattern"
For each of the **3,645 fibrosis genes**, we took its average level at each stage. That gives **5 numbers per gene**, which is its pattern.

| Gene | F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|---|
| FGR | -0.42 | -0.05 | 0.20 | 0.21 | 0.28 |
| GCLC | 0.20 | 0.25 | -0.06 | -0.28 | -0.71 |

Drawn as a line, FGR goes **up** and GCLC goes **down**.

## Part 2: Focus on the shape, not the size
Problem: one gene might go from 0.1 to 0.3, and another from -1 to +1. Both are "going up", just by different amounts.

We want to group genes by **shape**, so we **rescaled every gene to the same size**: average 0, spread 1. After that, a small riser and a big riser look identical, because only the shape is left.

## Part 3: Group genes with similar shapes (clustering)
We used a method called **k-means**. Think of sorting 3,645 drawings of lines into piles:
1. You decide how many piles you want. That number is **k**.
2. The computer puts each line into the pile whose lines look **most similar** to it.
3. It keeps moving lines between piles until each pile is as similar inside as possible.

**Important:** we never told the computer "make an early-rising group" or "make a late-falling group". It found the groups **by itself**, and we only gave them names **afterwards**. Your mentor specifically asked for this.

## Part 4: Choose how many groups (k)
We tried **k = 3, 4, 5, 6, 7 and 8** and checked two things for each.

### Check A: Silhouette score (are the groups clearly separate?)
For each gene it asks: is this gene much closer to its own group than to other groups?
- **High score:** groups are neat and well separated
- **Low score:** groups blur into each other

| k | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|
| Silhouette | 0.56 | 0.46 | 0.34 | 0.29 | 0.28 | 0.26 |

This always drops as k grows, because more groups means they sit closer together. So it can't decide k alone.

### Check B: Stability (do we get the same groups again?)
We **re-ran the clustering many times** on slightly different data and checked whether the same groups came back. A score near **1 means very stable**.

| k | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|
| Stability | 0.98 | 0.97 | **0.96** | 0.93 | 0.80 | 0.76 |

Stability stays high up to k = 5, then starts to drop. Above 5, the groups become unreliable.

### The decision: k = 5
- **k = 3 or 4:** too few. Different shapes got mixed together, for example two different "falling" patterns ended up in one pile.
- **k = 6 or more:** too many. One group just got split into two copies that look the same, and stability dropped.
- **k = 5:** the most groups that are **still stable**, and each one has a clearly different shape.

## The 5 groups the computer found

| | Shape | Genes |
|---|---|---|
| C1 | Rises early (F0→F1), then keeps rising | 927 |
| C2 | Flat, then shoots up late (F3→F4) | 1,514 |
| C3 | Rises early, then flattens | 197 |
| C4 | Drops in the middle (F1→F2) | 309 |
| C5 | Drops most at the end (F3→F4) | 698 |

## One honest note (from our later check)
- **The 5 shapes are very reliable.** They come back every time, even when we resample patients.
- **Which group each gene lands in is less certain** for genes on the borderline between groups. That's why each gene has a **membership_confidence** score in the file. When you talk about a specific gene in the paper, use the high-confidence ones.


---

## here each row we made values to avg 0 spread 1?

here each row we made values to avg 0 spread 1?


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\5.png]

Yes, exactly. **Each row (each gene) was rescaled separately**, using only its own 5 numbers.

Note that the table you pasted shows the values **before** this step. Here's how FGR gets rescaled.

## FGR, step by step
Its 5 values: **-0.42, -0.05, 0.20, 0.21, 0.28**

**Step 1: Find the average**
(-0.42 − 0.05 + 0.20 + 0.21 + 0.28) ÷ 5 = **0.04**

**Step 2: Subtract the average from each value** (this makes the average 0)
| F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|
| -0.46 | -0.09 | 0.16 | 0.17 | 0.24 |

**Step 3: Find the spread** (standard deviation, roughly how far values sit from the average)
For FGR it's about **0.26**.

**Step 4: Divide each value by the spread** (this makes the spread 1)
| F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|
| **-1.79** | **-0.38** | **0.59** | **0.64** | **0.94** |

## The same for GCLC
Average = -0.12 and spread = 0.35, which gives:
| F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|
| **0.91** | **1.05** | **0.17** | **-0.45** | **-1.68** |

## What changed and what didn't
- **The shape is unchanged.** FGR still goes up and GCLC still goes down. The F-stage where each gene rises or falls the most is the same.
- **Only the size changed.** Now every gene has average 0 and spread 1, so a gene that changes a little and a gene that changes a lot can be compared fairly.

**Why does this matter for clustering?** Without it, the computer would group genes by **how big** their change is, not by **when** they change. We wanted groups like "rises early" and "rises late", so shape was what mattered.

## One small detail
The values in your table (-0.42, -0.05, …) were **already standardised once before**, but in a different way: **within each study, across patients**. That made the 8 studies comparable.

The rescaling here is a **second, separate step**: **within each gene, across the 5 stages**. It's done only for clustering.

| | Done across | Purpose |
|---|---|---|
| 1st standardisation (earlier) | patients, within each study | make studies comparable |
| 2nd standardisation (Task 2) | the 5 stages, within each gene | compare shapes for clustering |

Sure. Stability answers one question:
> **"If the data were slightly different, would we still get the same groups?"**

If the groups only appear by luck, small changes to the data would break them. Real groups keep coming back.

## How we did it, step by step (for one k, say k = 5)

**Step 1: Make the "original" groups**
Cluster all 3,645 genes into 5 groups. This is our reference answer.

**Step 2: Shake the data a little**
Randomly pick **80% of the genes** (about 2,900) and leave out the other 20%.

**Step 3: Cluster again**
Run the clustering again on just those 80% of genes, into 5 groups.

**Step 4: Compare with the original**
For the genes in both runs, check whether they ended up grouped the same way.

**Step 5: Repeat 50 times**
Each time we leave out a different random 20%. Then we average the 50 scores.

Then we did the whole thing again for k = 3, 4, 6, 7 and 8.

## How "same grouping" is measured (the ARI score)
We use a score called the **Adjusted Rand Index (ARI)**. It looks at **pairs of genes**:
- If gene A and gene B were **together** in the original, are they **still together** in the new run?
- If they were **apart**, are they **still apart**?

The more pairs that agree, the higher the score:
- **ARI = 1:** identical groups every time, perfectly stable
- **ARI = 0:** no better than random grouping

The group **numbers** don't matter. If "group 2" is now called "group 4" but holds the same genes, it still counts as the same. Only **who is together with whom** matters.

## The results

| k | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|
| Stability (ARI) | 0.98 | 0.97 | **0.96** | 0.93 | 0.80 | 0.76 |

- **k = 3 to 5:** very stable (above 0.95), so the same groups come back almost every time
- **k = 6:** starting to slip
- **k = 7 and 8:** big drop, so the groups change from run to run and are not reliable

## How we picked k = 5
We combined three things:
1. **Stability:** we set a cutoff of **0.95**. k = 3, 4 and 5 pass; k = 6, 7 and 8 fail.
2. **Look at the shapes:** among the passing options, k = 3 and k = 4 **mixed different shapes together**, for example a "drops in the middle" pattern and a "drops at the end" pattern landing in one group.
3. **So k = 5** is the **largest number of groups that is still stable**, and each group has its own distinct shape.

## Two honest notes for your mentor
**1. The cutoff was chosen after looking at the results.** We picked "0.95" after seeing the curves, not before. That's common practice, but it should be stated. The full table is in the files, so your mentor can judge.

**2. We also did a harder stability test.** The test above leaves out **genes**. Later we also did a tougher one that resamples **patients**: pick patients at random with replacement, recompute the stage averages, then cluster again. That gave lower scores (**0.53 at k = 5**).

What it means:
- **The 5 shapes are real.** They came back every time (shape match 0.97–0.997).
- **Borderline genes switch groups**, especially between the three "rising" groups, which differ only in timing.

That's why each gene has a **membership_confidence** score. Both test results are in `task2_choosing_k.csv` and the Task 2 README.


---

## what it is..tell me clearly in simple words

what it is..tell me clearly in simple words


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\6.png]

This is **`task2_bootstrap_shape_stability.csv`**. It answers two questions:
1. **Are the 5 shapes real?**
2. **How sure are we about which genes belong to each shape?**

## How it was made
We repeated this **100 times**:
1. **Pick patients at random** from the real data. Some patients get picked twice and some not at all. This mimics "what if we had recruited a slightly different set of patients?"
2. **Recompute each gene's F0–F4 pattern** using those patients.
3. **Cluster again** into 5 groups.
4. **Match each new group to the original group it looks most like.**

Then we checked the results.

## The columns

### `median_shape_corr`: does the shape come back?
For each of the 100 runs, we compared the new group's shape with the original shape. The score is a correlation, where **1 means an identical shape**. "Median" is the typical value across the 100 runs.

| Cluster | Typical shape match |
|---|---|
| C1 Early increase | 0.981 |
| C2 Late increase | **0.997** |
| C3 Early rise, plateau | 0.968 |
| C4 Mid decrease | 0.967 |
| C5 Late decrease | **0.993** |

All are close to 1, so **all 5 shapes are real and come back almost every time**. ✅

### `min_shape_corr`: the worst run out of 100
This is the single worst match across all 100 runs.
- **C2 (0.972):** even in its worst run, the shape was nearly identical. Very solid.
- **C1 (0.829) and C4 (0.752):** still similar in the worst run.
- **C3 (-0.428) and C5 (-0.516):** **negative!** In at least one run, this shape **was not found at all**. The matching had to pair it with a different shape.

A negative minimum doesn't mean the cluster is fake. The **median** (0.97 and 0.99) shows it comes back in the typical run. It means that **occasionally**, with an unlucky patient sample, that pattern merges into a neighbouring group. C3 is small (197 genes), so it's the easiest to lose.

### `genes_confidence>=0.8`: how many genes reliably stay in their group
For each gene, we counted **how many of the 100 runs it stayed in its own group**. If it stayed in **80 or more**, we call it **high-confidence**.

| Cluster | All genes | High-confidence genes | % reliable |
|---|---|---|---|
| C1 | 927 | 47 | 5% |
| C2 | 1,514 | 841 | **56%** |
| C3 | 197 | 36 | 18% |
| C4 | 309 | 78 | 25% |
| C5 | 698 | 423 | **61%** |

### `n_genes`
The total number of genes in each group, from the original clustering.

## What it means, in one picture

```
The SHAPES are solid    ✅  (median match 0.97–0.997)
Gene MEMBERSHIP varies  ⚠️  (many genes sit on the border)
```

**Why do genes switch?** C1, C2 and C3 are all "rising" shapes, differing only in **when** they rise. A gene that rises "a bit early, a bit late" sits on the border and can fall either side depending on which patients are sampled.

## How to use this in the paper
- ✅ **Safe:** "We identified five reproducible expression trajectories across fibrosis stages."
- ✅ **Safe:** "CCN2 is a high-confidence member of the late-increase cluster." Check its `membership_confidence` in `task2_gene_clusters.csv`.
- ⚠️ **Avoid:** talking about a gene's cluster if its confidence is low.
- **C2 and C5** are the most trustworthy groups, with large stable cores.


---

## now explain this clearly in simple words

now explain this clearly in simple words


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\7.png]

This is **`task2_choosing_k.csv`**. It's the table we used to decide **how many groups (k)** to make. Each row is one choice of k (3 to 8), and each column is one test of how good that choice is.

## The table, rounded so it's easier to read

| k | silhouette | stability (mean) | stability (sd) | patient bootstrap (mean) | patient bootstrap (sd) |
|---|---|---|---|---|---|
| 3 | 0.56 | 0.98 | 0.02 | 0.75 | 0.04 |
| 4 | 0.46 | 0.97 | 0.03 | 0.56 | 0.07 |
| **5** | **0.34** | **0.96** | **0.03** | **0.53** | **0.08** |
| 6 | 0.29 | 0.93 | 0.06 | 0.46 | 0.05 |
| 7 | 0.28 | 0.79 | 0.14 | 0.42 | 0.05 |
| 8 | 0.26 | 0.76 | 0.14 | 0.37 | 0.05 |

## What each column means

### `silhouette`: are the groups neatly separated?
It's measured on the full data. Higher means groups are more clearly apart, with 1 the best.
- It **always drops** as k goes up: more groups means they sit closer together, so they look less separate.
- So it can't choose k on its own. It just says **fewer groups look neater**.

### `stability_ARI_mean`: do the same groups come back? (gene test)
- We left out a random 20% of **genes**, re-clustered and compared with the original, 50 times. This column is the average score, where 1 means identical groups every time.
- **k = 3, 4 and 5 are all above 0.95**, so very stable.
- At **k = 7 and 8 it drops to about 0.78**, so those groups are unreliable.

### `stability_ARI_sd`: how much that score varied across the 50 runs
- **Small** (0.02–0.03 for k = 3 to 5) means the result was consistent every time.
- **Bigger** (0.14 for k = 7 and 8) means it was sometimes good and sometimes bad, so unreliable.

### `patient_bootstrap_ARI_mean`: do the same groups come back? (patient test, the harder one)
- We picked **patients** at random (with replacement), rebuilt every gene's F0–F4 pattern and re-clustered, 50 times.
- This is a **tougher test**, because it changes the actual data, not just which genes are included. So the scores are lower: **0.75 at k = 3**, falling to **0.37 at k = 8**.

### `patient_bootstrap_ARI_sd`
How much the patient test varied across its 50 runs. It's small for every k (0.04–0.08), so these averages are trustworthy.

## How we chose k = 5
**Rule:** the largest k where the gene stability stays **≥ 0.95**.
- k = 3, 4 and 5 pass. k = 6, 7 and 8 fail.
- The largest that passes is **k = 5**.

**Why not k = 3**, even though it scores best on everything?
- With only 3 groups, **clearly different shapes get forced together**. For example, "drops in the middle" and "drops at the end" became one group, and "rises early" and "rises late" got mixed.
- That would hide exactly the patterns your mentor asked us to find (early increase, late increase and so on).
- k = 5 keeps them apart while still being stable.

## ⚠️ What to say honestly to your mentor
1. **Every score is best at k = 3.** We chose k = 5 because it gives **more distinct, meaningful shapes** while staying stable. That's a judgment call.
2. **The patient test is only moderate at k = 5 (0.53).** The **shapes** are reliable, but **individual genes on the borders** move between groups. That's why we added the confidence score per gene.

## About the green triangles in Excel
Those little green corners are only an **Excel warning**: it's surprised by the very long decimal numbers. The data is fine. You can ignore them, or select the cells and click **"Ignore Error"**.


---

## explain this clearly in simple words

explain this clearly in simple words


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\8.webp]

This is the picture version of the table we just went through. It has **two panels**, and both help answer **"how many groups should we make?"**

The **light blue vertical bar** in both panels marks our choice: **k = 5**.

## Left panel: Silhouette score
**The question:** are the groups clearly separate from each other?
- **Bottom axis:** the number of groups (k = 3 to 8)
- **Side axis:** the silhouette score, where higher means neater, more separate groups

**What you see:**
- A **steep drop** from k = 3 to k = 5 (0.56 → 0.34)
- After k = 5 the line **flattens out** (0.29, 0.28, 0.26)

**What it means:**
- Fewer groups always look neater, so k = 3 scores highest. That's expected.
- But notice the **bend ("elbow") around k = 5**. After 5, adding more groups barely changes the score. The new groups aren't adding much new structure, which supports stopping around 5.

## Right panel: Stability
**The question:** if we change the data a little, do we get the same groups again?
- **Side axis:** stability score (ARI), where 1 means identical groups every time

There are **two lines**, for two different tests:

### Black line with circles: gene test (the easier test)
- We left out 20% of genes at random, re-clustered and compared, 50 times.
- **High and flat (about 0.96–0.98) for k = 3, 4 and 5**, then it **drops** at k = 6, 7 and 8.

### Red dashed line: our cutoff (0.95)
- Points **above** the line count as "stable enough".
- **k = 3, 4 and 5 are above it**, and k = 6 falls just below.
- So **k = 5 is the largest k that's still above the line**, and that's why we chose it.

### Purple dashed line with squares: patient test (the harder test)
- We resampled **patients**, rebuilt the patterns and re-clustered, 50 times.
- **Always lower** than the black line (0.75 down to 0.37), because this test changes the real data more.
- It falls steadily as k grows. There's no sudden collapse at any point.

### The little vertical bars (error bars)
These show **how much the score jumped around** across the 50 repeats:
- **Short bar:** the result was consistent every time
- **Long bar:** sometimes good, sometimes bad, so unreliable

At **k = 7 and 8** the black line's bars are **very long**. Those groupings are unstable.

## The whole picture in 3 lines
1. **k = 3** scores best on everything, but it's **too simple**: it mixes different shapes together.
2. **k = 7 or 8** is **too many**: the groups fall apart and become unreliable.
3. **k = 5** sits in the sweet spot. It's **still stable** (above the red line), it's **where the silhouette curve flattens**, and it keeps the **5 different shapes** separate.

## The one honest point for your mentor
The **purple line (patient test) at k = 5 is only 0.53**. That doesn't mean the clusters are fake:
- **The 5 shapes come back reliably** (we checked: match 0.97–0.997).
- **Borderline genes switch between neighbouring groups.**

So **the patterns are trustworthy; individual gene assignments on the border are less so**. That's why every gene has a confidence score.


---

## explain this clearly in simple words

explain this clearly in simple words


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\9.webp]

This heatmap shows **all 3,645 fibrosis genes in one picture**.

## How to read it

**Each thin horizontal line is one gene.** There are 3,645 lines stacked on top of each other, so thin that they blend into blocks.

**Each column is one fibrosis stage**: F0, F1, F2, F3 and F4, left to right.

**The colour shows the gene's level at that stage:**

| Colour | Meaning |
|---|---|
| 🔴 **Red** | **higher** than that gene's own average |
| ⚪ **White** | about average |
| 🔵 **Blue** | **lower** than that gene's own average |

**Important:** the colours are about **each gene compared with itself**, after the rescaling we did (average 0, spread 1). Red doesn't mean "a lot of this gene in the liver". It means **"this gene is at its highest point here"**.

**The black lines** split the genes into the **5 groups (C1–C5)**. Within each group, the genes at the top match the group's shape best.

## Reading each block (left → right = F0 → F4)

### C1: Early increase (927 genes)
🔵 → ⚪ → ⚪ → 🟠 → 🔴
Blue at F0, **already lighter by F1**, then steadily redder. The rise starts **early**.

### C2: Late increase (1,514 genes, the biggest group)
🔵 → 🔵 → ⚪ → 🟠 → 🔴🔴
Stays blue for a long time, then turns **deep red only at F4**. The big jump comes **late**, at the step into cirrhosis.

### C3: Early rise, then plateau (197 genes)
🔵🔵 → ⚪ → 🟠 → 🔴 → 🟠
Very blue at F0, rises quickly, **reddest at F3**, and slightly lighter at F4. Remember that the F4 dip **wasn't significant** in Task 3, so it's really "rises, then levels off". These are the **cell-division genes**.

### C4: Mid decrease (309 genes)
🔴 → 🔴 → ⚪ → 🔵 → 🔵
High at F0–F1, then **drops at F1→F2**. These genes switch off **in the middle**.

### C5: Late decrease (698 genes)
🟠 → 🟠 → ⚪ → 🔵 → 🔵🔵
Starts high, slowly drops, then **falls sharply at F4**. These are the **normal liver metabolism genes** shutting down in cirrhosis.

## The big picture in one look

```
Top part (C1, C2, C3)    → blue on the left, red on the right = genes RISING
Bottom part (C4, C5)     → red on the left, blue on the right = genes FALLING
```

- **About 72% of genes rise** (C1 + C2 + C3 = 2,638 genes) and **about 28% fall** (C4 + C5 = 1,007 genes).
- The **darkest colours are in the F4 column** for C2 (deep red) and C5 (deep blue). That matches Task 3's finding that **the biggest change happens at F3→F4**.

## Why the colour is so even inside each block
Each block looks almost like a solid colour band because the clustering put genes with **the same shape** together. That's what a clean result looks like. If the clustering had failed, the blocks would look like random noise.

Task 3 answers one question:
> **"At which step does the liver change the most: F0→F1, F1→F2, F2→F3 or F3→F4?"**

We answered it in **two ways**: a simple way, as the mentor asked first, and a proper statistical way, as the mentor also asked.

## Way 1: The simple way (difference of averages)
For each gene, subtract one stage's average from the next stage's average.

**Example: FGR**
| | F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|---|
| Average | -0.42 | -0.05 | 0.20 | 0.21 | 0.28 |

| Step | Calculation | Change (Δ) |
|---|---|---|
| F0→F1 | -0.05 − (-0.42) | **+0.36** |
| F1→F2 | 0.20 − (-0.05) | +0.25 |
| F2→F3 | 0.21 − 0.20 | +0.01 |
| F3→F4 | 0.28 − 0.21 | +0.08 |

So for FGR, the biggest change is at **F0→F1**. We did this for **all 3,645 genes**, giving 4 changes per gene.

**The problem:** averages can mislead. They don't tell you whether a change is **real or just noise**. That's why your mentor said: *"Do not rely only on differences of stage means."*

## Way 2: The proper way (statistics on real patients)
For each gene and each step, we took the **actual patients** (not averages) and asked:
> **"Are patients at the next stage really different from patients at this stage, or could it be chance?"**

We had to handle **2 tricky problems** first.

### Problem 1: The studies are mixed differently
Some studies have mostly early-stage patients, and others mostly late-stage ones. For example, GSE193066 has 71 F2 patients but only 1 at F4.

Each study measured genes slightly differently, so if we just pooled everyone, **study differences could look like stage differences**.

**Fix:** we told the test which study each patient came from. It then compares stages **only within the same study** and combines the results:
```
gene level  =  stage effect  +  study effect
                  ↑                  ↑
          what we want       removed (not mixed in)
```
The "stage effect" is the **real change** between the two stages, called **β (beta)**.

### Problem 2: Some patients were biopsied twice
58 patients in GSE193066 had 2 biopsies. Counting them twice would be unfair.

**Fix:**
- **Both biopsies at the same stage** (28 patients): **average** them into one.
- **Biopsies on both sides of a step**, for example one at F1 and one at F2 (24 patients): **keep only one**, chosen at random.

Now **every patient counts once**.

### Then the test itself
For each gene × each step, we get:
- **β:** how big the change is
- **p-value:** how likely the change is to be chance
- **FDR (q-value):** the p-value corrected for testing thousands of genes at once

## Step 3: Count the genes that really change
A gene counts as **"substantially changing"** at a step if **both** hold:
1. **q < 0.05**, so it's statistically real
2. **|β| ≥ 0.2**, so the change is big enough to matter

| | F0→F1 | F1→F2 | F2→F3 | F3→F4 |
|---|---|---|---|---|
| Genes changing | 1,165 | 1,175 | 1,117 | 936 |

**Wait, F3→F4 looks smallest?** That's misleading, and here's why.

## Step 4: Make the comparison fair
F4 has only **34 patients**, far fewer than the other stages (109–166).
**Fewer patients means it's harder to prove a change is real**, even when the change is big. Think of judging a class average from 34 students versus 160.

So we did **two fairness checks**.

### Check A: Give every step the same number of patients
We randomly picked **30 patients per stage**, balanced across the same studies, for **every** step. That gives each step equal power. We repeated it **50 times**.

| | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Genes changing (median) | 0 | 0 | 2 | **311** |

With a fair comparison, **F3→F4 wins by far**.

### Check B: Look at the size of change (doesn't depend on patient numbers)
| | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Typical change size | 0.19 | 0.19 | 0.22 | **0.38** |

**F3→F4 changes are about twice as big** as any other step.

## The answer
> **The largest molecular change happens at F3→F4, the step into cirrhosis.**

- **Earlier steps:** many **small** changes
- **F3→F4:** fewer genes reach significance (only because of the small F4 group), but the changes are **much bigger**

## Extra findings
- **F0→F1** is almost **only increases** (1,135 up vs 30 down). The liver first **switches genes on**.
- **Switching genes off** starts mainly at **F1→F2** (528 down).


---

## so finally how we told that f3-f4 is the biggest element

so finally how we told that f3-f4 is the biggest element

We used **3 pieces of evidence**, and **all 3 point to F3→F4**.

## Evidence 1: The changes are biggest at F3→F4
We measured **how much** each gene changes at each step, then took the typical (median) change across all 3,645 genes:

| Step | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Typical change | 0.19 | 0.19 | 0.22 | **0.38** |

F3→F4 is about **2× bigger** than any other step. This measure **doesn't depend on how many patients** are in each stage, so it's a fair comparison.

## Evidence 2: More genes make big changes at F3→F4
We counted the genes whose change is **at least 0.2**:

| Step | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Genes with a big change | 1,699 | 1,693 | 2,043 | **2,710** |

F3→F4 has the **most genes** with big changes.

## Evidence 3: In a fair contest with equal patients, F3→F4 wins clearly
F4 has only 34 patients, so we gave **every step the same 30 patients per stage**, balanced across studies, and re-tested 50 times:

| Step | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Genes significantly changing | 0 | 0 | 2 | **311** |

With equal patients, **only F3→F4 shows many significant changes**.

## Why not just count significant genes using all patients?
If we had done only that, we would have seen:

| Step | F0→F1 | F1→F2 | F2→F3 | F3→F4 |
|---|---|---|---|---|
| Significant genes (all patients) | 1,165 | 1,175 | 1,117 | **936** |

That makes F3→F4 look **smallest**, but that's **unfair**:
- F0→F1 compares 152 vs 166 patients, so it has lots of power to detect even tiny changes.
- F3→F4 compares 118 vs **34** patients, so there's less power and it's harder to prove changes.

It's like comparing a test with 160 students to one with 34. The bigger class will always look "more certain". Once we **removed this unfairness** (Evidence 3), F3→F4 came out on top.

## The conclusion in one sentence
> **F3→F4 has the biggest changes in size (Evidence 1), the most genes with big changes (Evidence 2), and the most significant genes when every step gets equal patients (Evidence 3), so the largest molecular change happens at the step into cirrhosis.**

All these numbers are in `task3_transition_summary.csv`, and the picture is `task3_transition_comparison.png`.


<sub>ran — Bash: Get real EMT enrichment numbers for the example</sub>

Task 4 answers one question:
> **"What biological jobs are the genes in each group doing?"**

## Step 1: Make separate gene groups
Your mentor said **don't mix all 4,692 genes together**, because rising and falling genes do different jobs and mixing them would blur the answer. So we made separate groups:

| Group | Genes |
|---|---|
| Fibrosis-only, rising | 1,301 |
| Fibrosis-only, falling | 652 |
| Inflammation-only, rising | 597 |
| Inflammation-only, falling | 450 |
| Shared, rising | 1,335 |
| Shared, falling | 356 |
| Cluster C1 to C5 (from Task 2) | 927 / 1,514 / 197 / 309 / 698 |

We also made an extra **check** version of each cluster, using only its **high-confidence** genes.

## Step 2: Get 4 "dictionaries" of gene jobs
Scientists have already grouped genes by job into **pathways**. We used 4 well-known collections, all from **MSigDB** (the Broad Institute):

| Database | What it contains | Example pathway |
|---|---|---|
| **GO Biological Process** | very detailed processes | "collagen fibril organization" |
| **KEGG** | classic textbook pathways | "fatty acid metabolism" |
| **Reactome** | detailed molecular steps | "collagen formation" |
| **Hallmark** | 50 big, clean themes | "inflammatory response" |

## Step 3: Test each group against each pathway (the core idea)
Here's a **real example** from your results.

**Group:** shared rising genes (1,335 genes)
**Pathway:** Hallmark "Epithelial–mesenchymal transition" (EMT), the scar-forming process (190 genes)

**Question:** how many of our 1,335 genes are EMT genes?
- **We found 77.**
- **How many would we expect by pure chance?**
  EMT genes make up 190 of the 14,794 tested genes, about 1.3%.
  1.3% of 1,335 ≈ **17 genes**.
- **77 found vs 17 expected**, which is about **4.5× more than chance** (the "fold enrichment").

The **statistical test** (hypergeometric test) then asks how likely it is to get 77 when you expect 17. The answer is **practically zero**: the value is too small for the computer to print. **So EMT is strongly enriched**, and these genes really are about scar formation.

The genes responsible include **COL1A1, COL1A2, LOXL1, FBN1, TIMP1, LUM, VCAN…**, all classic scar-tissue genes.

We repeated this for **every pathway × every group × every database**, which is thousands of tests.

## Step 4: Use the correct background (your mentor's most important point)
The **"expected by chance"** number depends on what you compare against.

❌ **Wrong way (the default in most tools):** compare against **all ~20,000 human genes**.
✅ **Our way:** compare against **only the 14,794 genes we actually tested**.

**Why does it matter?** About 5,000 human genes were **never measured** in all our studies, so they **had no chance** to appear in our lists. Including them makes "expected by chance" too small, and everything looks more significant than it really is.

**Simple analogy:** you pick 10 students from **one classroom of 30** and find 5 wear glasses. Is that unusual? You should compare against **that classroom**, not against the whole school.

**How we made sure it was applied:**
- We removed untested genes from every pathway **before** testing.
- We ran the test **on our own computer**, not a website, because many websites ignore custom backgrounds.
- We **checked one result by hand**, and it matched the tool exactly.

## Step 5: Keep only the real results, and save the details
- **BH-FDR < 0.05:** because we ran thousands of tests, some would look significant by luck. The FDR correction removes those. Only pathways that pass are called significant.
- For every pathway we kept, as your mentor asked:

| Column | Meaning | In the EMT example |
|---|---|---|
| overlap (gene count) | our genes in the pathway | 77 |
| gene_ratio | overlap ÷ group size | 77 ÷ 1,335 = 0.058 |
| bg_ratio | pathway size ÷ background | 190 ÷ 14,794 = 0.013 |
| fold_enrichment | how many times more than chance | 4.5× |
| q_value | FDR-corrected significance | ≈ 0 |
| **genes** | **which genes caused it** | COL1A1, LOXL1, … |

## Step 6: Make the pictures
- **Dot plots:** one per group, showing its top pathways
- **Combined heatmaps:** one per database, all groups side by side, so you can see **which biology belongs to which group**

## The result in simple words

| Group | Main biology |
|---|---|
| Rising with fibrosis | immune activation, inflammation |
| Rising in both (shared) | **scar tissue** (collagen, EMT) |
| Falling groups | **normal liver metabolism** being lost |
| C3 cluster | **cell division** |
| Inflammation-only | very weak signal |

In total, that's **16 groups × 4 databases = 64 separate enrichment tables**, all in `Paper1_Results/Task4/enrichment_tables/`.


---

## Use BH-FDR < 0.05  what is this

Use BH-FDR < 0.05  what is this

**BH-FDR < 0.05** is a rule for deciding which results to trust when you run **many tests at once**. Here it is step by step.

## First: what is a p-value?
Every test gives a **p-value**, which answers:
> "If there were **no real effect**, how likely would I be to see a result this strong just by luck?"

- **p = 0.01:** only a 1% chance it's luck, so probably real
- **p = 0.50:** a 50% chance it's luck, so not convincing

The usual rule is **p < 0.05**, meaning less than a 5% chance of luck, so we call it real.

## The problem: we ran thousands of tests
In Task 4 we tested **thousands of pathways**. Say we test **1,000 pathways**, and none of them are truly related to our genes. With the rule "p < 0.05", **5% of them will still pass by pure luck**:
> 1,000 × 5% = **50 fake "significant" pathways**

Like flipping a coin 1,000 times: some runs of heads will happen by chance, and they don't mean the coin is special. So with many tests, **p < 0.05 alone is not safe**.

## The solution: FDR (False Discovery Rate)
**FDR** changes the question to:
> "Of all the pathways I call significant, **what fraction are probably fake?**"

**FDR < 0.05** means **at most 5% of our significant results are expected to be false**. So if we report 100 significant pathways, about **95 or more are real** and at most 5 may be luck.

## What is BH?
**BH** stands for **Benjamini–Hochberg**, the two scientists who invented the method. It's the most common way to control FDR.

### How BH works, in simple steps
1. **Sort** all p-values from smallest to largest.
2. **Give each one a stricter threshold** based on its rank:
   - the **1st** (smallest) must beat 0.05 × 1/1000
   - the **2nd** must beat 0.05 × 2/1000
   - the **3rd** must beat 0.05 × 3/1000
   - …and so on
3. **Keep everything up to the last one that passes.**

The computer turns each p-value into an adjusted number called a **q-value** (the "q_value" column in your files). Then the rule is simply:
> **q < 0.05 → significant ✅**
> **q ≥ 0.05 → not significant ❌**

### A tiny example with 5 tests

| Pathway | p-value | Rank | BH threshold (0.05 × rank ÷ 5) | Passes? |
|---|---|---|---|---|
| A | 0.001 | 1 | 0.01 | ✅ |
| B | 0.008 | 2 | 0.02 | ✅ |
| C | 0.020 | 3 | 0.03 | ✅ |
| D | 0.041 | 4 | 0.04 | ❌ |
| E | 0.300 | 5 | 0.05 | ❌ |

Look at **pathway D**: its p-value is 0.041, which **would pass** the normal "p < 0.05" rule, but **BH rejects it**. That's BH protecting us from luck.

## Where we used it in your project

| Task | What was tested many times | BH-FDR used |
|---|---|---|
| Finding the 4,692 genes | ~14,794 genes | ✅ q < 0.05 |
| Task 3 | 3,645 genes × 4 steps | ✅ q < 0.05 |
| Task 4 | thousands of pathways | ✅ q < 0.05 |

## In one sentence
> **BH-FDR < 0.05 means: "after correcting for running thousands of tests, we expect at most 5% of our significant results to be false."**

That's why your mentor asked for it. It makes the results **trustworthy**, not just lucky.


---

## what is that fib_q score

what is that fib_q score


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\10.png]

**fibrosis_q** is the **q-value** for each gene's fibrosis result. It's the **BH-FDR** number we just talked about.

## What it means
It answers:
> **"How likely is it that this gene's link to fibrosis is just luck?"**

- **Smaller q means more certain the gene is truly linked to fibrosis.**
- A gene was only included if **q < 0.05**.

## ⚠️ The numbers you see are cut off
Excel is showing **1.6154774**, but that's **not** the real value. The column is too narrow, so the end of the number is hidden. The real values are **tiny**:

| Gene | What Excel shows | Real value | Written out |
|---|---|---|---|
| NALCN | 1.6154774 | **1.6 × 10⁻³⁷** | 0.000…00016 (36 zeros) |
| STMN2 | 5.5904520 | **5.6 × 10⁻⁵¹** | 0.000…00056 (50 zeros) |
| LAMC3 | 3.7627113 | **3.8 × 10⁻⁴⁰** | 0.000…00038 (39 zeros) |

These are **far, far smaller than 0.05**, so **we are extremely sure these genes are truly linked to fibrosis**.

### How to see the full number in Excel
- **Easy way:** click a cell in column E and look at the **formula bar** at the top. The full number appears there, for example `1.61547744E-37`.
- **Or widen the column:** double-click the line **between E and F** in the column headers.
- **Or format it:** select column E → right-click → **Format Cells** → **Scientific** → OK.

`E-37` means "× 10⁻³⁷", so the decimal point moves 37 places to the left.

## How fibrosis_q was calculated (simple version)
1. **In each study separately**, we measured how strongly the gene goes up or down with fibrosis stage (Spearman ρ) and got a p-value.
2. **Combined the studies:** we merged the p-values from all 5 staged studies into **one p-value** (Fisher's method). Agreement across many studies gives much stronger evidence than any single study.
3. **Corrected for testing many genes:** we tested about **14,794 genes**, so we applied **BH-FDR** correction. That turns the p-value into the **q-value**.

## Why are the numbers so incredibly small?
Because the evidence is **very strong**:
- **5 studies** all agree on the direction
- **hundreds of patients** in total
- these are the **top 20 genes**, the strongest of all

When many independent studies all say the same thing, the chance of it being luck becomes vanishingly small.

## Summary
| Column | Question it answers | For NALCN |
|---|---|---|
| fibrosis_rho | **How strongly** does it change with fibrosis? | 0.58 (strong, rising) |
| fibrosis_q | **How sure** are we it's real? | 1.6 × 10⁻³⁷ (extremely sure) |

The pattern for each gene is just **5 numbers**: its average level at F0, F1, F2, F3 and F4. Here's how we got from raw lab data to those 5 numbers.

## Step 1: Start with the raw measurements
Each of the **668 staged liver biopsies** was sequenced, which tells us **how much of each gene** that liver was making. These are raw counts, like "the liver made 748 copies of gene GCLC".

## Step 2: Put the raw numbers on a log scale
Raw counts range from about 0 to over 100,000, so a few huge genes would dominate everything. Taking the **log** shrinks the scale so all genes are comparable:
```
748 copies  →  log  →  6.1
```

## Step 3: Make the studies comparable (z-score within each study)
**The problem:** the samples come from **5 different studies**, each done in a different lab with different machines. The same gene can read "high" in one study and "low" in another just because of the lab.

**Fix:** within **each study** and for **each gene**, we rescaled the values so that:
- the **average across that study's patients = 0**
- the **spread = 1**

This value is called **value_z**:
- **positive** means higher than average **for that gene in that study**
- **negative** means lower than average

Now a patient from study A and a patient from study B can be compared fairly.

## Step 4: Group patients by fibrosis stage
Every biopsy has a fibrosis stage from the pathologist:

| Stage | F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|---|
| Biopsies | 152 | 168 | 186 | 127 | 35 |

## Step 5: Average each gene within each stage
For each gene, take all F0 patients and average their value_z, then do the same for F1, F2, F3 and F4.

**Example: FGR**
| | F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|---|
| Average of… | 152 patients | 168 patients | 186 patients | 127 patients | 35 patients |
| **FGR** | **-0.42** | **-0.05** | **0.20** | **0.21** | **0.28** |

**These 5 numbers are FGR's pattern.** It goes up with fibrosis.

We did this for **all 3,645 fibrosis genes**. The result is the file **`genes_by_fibrosis_stage.csv`**: 3,645 rows × 5 stage columns.

## Step 6: Rescale each pattern for clustering
As we discussed earlier, we rescaled **each gene's 5 numbers** to average 0 and spread 1, so genes are grouped by **shape**, not size:
```
FGR:  -0.42, -0.05, 0.20, 0.21, 0.28
         ↓ rescale
      -1.79, -0.38, 0.59, 0.64, 0.94
```
These rescaled patterns are what went into the clustering.

## The whole journey in one picture

```
Raw counts per biopsy           (748 copies)
        ↓  log
Log expression                  (6.1)
        ↓  z-score within each study  → makes 5 labs comparable
value_z per patient             (-1.4)
        ↓  group by stage, then average
5 stage averages = PATTERN      (F0 … F4)
        ↓  z-score within each gene   → keeps only the shape
Shape used for clustering
```

## One honest note
The stage averages **mix patients from different studies**, and each study has a different mix of stages. We checked whether this distorts the patterns by recomputing them with a **study correction**. The patterns were **almost identical** (correlation **0.998**), so this mixing doesn't affect the result.


---

## how the membership confidence is calculated

how the membership confidence is calculated


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\11.png]

**membership_confidence** answers one question:
> **"If we had studied a slightly different group of patients, would this gene still land in the same cluster?"**

It's a number from **0 to 1**:
- **1.00:** stayed in its cluster **every time**, very sure
- **0.50:** stayed only half the time, unsure
- **0.80 or more:** we call it **high-confidence**

## How it's calculated, step by step

### Step 1: Pretend to recruit a new set of patients
We can't recruit new patients, so we **simulate it** by drawing patients at random from our own data, **with replacement**:
- Some patients get picked **twice**
- Some get picked **once**
- Some **not at all**

We draw within each study, so each study keeps its size. This is called a **bootstrap**. It gives a "new" patient group that's similar to the original but slightly different, like a second real study would be.

### Step 2: Rebuild every gene's pattern
Using these new patients, recompute each gene's average at F0, F1, F2, F3 and F4, then rescale it as before.

### Step 3: Cluster again into 5 groups
Run the same clustering (k-means, k = 5) on the new patterns.

### Step 4: Match the new groups to the original groups
The computer numbers groups randomly, so the new "group 3" might really be the original "group 1". We match each new group to the **original group with the most similar shape**, for example "the new group that rises late = original C2".

### Step 5: Check each gene
For every gene, ask: **did it land in the same group as originally?** ✅ yes or ❌ no.

### Step 6: Repeat 100 times, then count
```
membership_confidence = (number of times it stayed in its group) ÷ 100
```

## Examples from your screenshot

| Gene | Stayed in C1 | Confidence | Meaning |
|---|---|---|---|
| BAK1 | 85 of 100 runs | **0.85** | ✅ high confidence, a solid C1 gene |
| DOCK8 | 83 of 100 | **0.83** | ✅ high confidence |
| COL5A2 | 82 of 100 | **0.82** | ✅ high confidence |
| ACLY | 76 of 100 | 0.76 | fairly sure, just below the cutoff |
| COMMD5 | 61 of 100 | 0.61 | unsure, sometimes lands in another group |
| **CEP135** | 38 of 100 | **0.38** | ⚠️ low, **usually lands elsewhere** |

## Why is CEP135 low even though it fits the shape almost perfectly?
Look at its columns:
- **corr_to_centroid = 0.9993:** an almost perfect match to C1's shape
- **membership_confidence = 0.38:** but it often switches groups

These two measure **different things**:

| Column | Question |
|---|---|
| **corr_to_centroid** | How well does the gene match its group's shape **in our actual data**? |
| **membership_confidence** | Does it **stay** in that group when the patients change? |

CEP135 changes **only a little** across stages: from -0.12 at F0 to 0.20 at F4, a small rise. A small change means **small random differences between patients can shift its shape**, so it easily moves to a neighbouring group like C2.

Genes with **big, clear changes** (BAK1: -0.38 → 0.63) stay put, because random noise can't push them around.

**Simple analogy:** a person standing right at the border between two countries gets counted in different countries depending on a small step. A person deep inside one country is always counted there.

## How to use it
- **Talking about a specific gene's cluster in the paper:** pick genes with **confidence ≥ 0.8**.
- **Talking about the overall pattern of a cluster:** all genes are fine, because the **shapes** themselves are very reliable.


---

## what is pct of fibrosis genes

what is pct of fibrosis genes


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\12.png]

**pct_of_fibrosis_genes** means **"what percentage of all the fibrosis genes are in this cluster"**.

## How it's calculated
We clustered **3,645 fibrosis genes** in total. For each cluster:
```
pct = (genes in this cluster ÷ 3,645) × 100
```

| Cluster | Genes | Calculation | % |
|---|---|---|---|
| C1 Early increase | 927 | 927 ÷ 3,645 × 100 | **25.4%** |
| C2 Late increase | 1,514 | 1,514 ÷ 3,645 × 100 | **41.5%** |
| C3 Early rise, plateau | 197 | 197 ÷ 3,645 × 100 | **5.4%** |
| C4 Mid decrease | 309 | 309 ÷ 3,645 × 100 | **8.5%** |
| C5 Late decrease | 698 | 698 ÷ 3,645 × 100 | **19.1%** |
| **Total** | **3,645** | | **100%** |

## What it tells you
- **C2 is the biggest group (41.5%).** Almost half of all fibrosis genes **rise late**, at the step into cirrhosis.
- **C3 is the smallest (5.4%).** Only a few genes follow the "early rise, then plateau" shape. These are the cell-division genes.
- **Rising genes** (C1 + C2 + C3) = **72.3%**
- **Falling genes** (C4 + C5) = **27.6%**

So **most fibrosis genes go up**, and **most of the change happens late**.

## The other columns (mean_F0 to mean_F4)
These are the **average pattern of each cluster**: the average of all its genes at each stage.

For example, **C2 (late increase)**:
| F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|
| -0.23 | -0.15 | -0.03 | 0.28 | **0.88** |

It stays low through F0–F2, starts rising at F3, then **jumps to 0.88 at F4**. That's why it's called "late increase".

These averages use the **original scale** (value_z), not the rescaled shapes, so you can see **how big** the changes really are. For example, C2 rises much more (to 0.88) than C1 (to 0.52).


---

## how the stability_ari is calculated

how the stability_ari is calculated


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\13.png]

**stability_ARI_mean** answers:
> **"If we cluster again on slightly different data, do the same genes still end up together?"**

There are two parts to explain: **how one ARI score is calculated**, and **how we got the mean**.

## Part 1: How one ARI score is calculated
ARI stands for **Adjusted Rand Index**. It compares **two groupings** of the same genes.

### The key idea: look at pairs of genes
For **every pair** of genes, ask:
- Were they **together** in the original grouping, and are they **still together** now? ✅ agree
- Were they **apart** originally, and are they **still apart**? ✅ agree
- Otherwise ❌ disagree

### A tiny example with 4 genes (A, B, C, D)

**Original grouping:** Group 1 = {A, B}, Group 2 = {C, D}
**New grouping:** Group 1 = {A, B, C}, Group 2 = {D}

Check all 6 pairs:

| Pair | Original | New | Agree? |
|---|---|---|---|
| A–B | together | together | ✅ |
| A–C | apart | together | ❌ |
| A–D | apart | apart | ✅ |
| B–C | apart | together | ❌ |
| B–D | apart | apart | ✅ |
| C–D | together | apart | ❌ |

**3 of 6 pairs agree, so the Rand Index = 3 ÷ 6 = 0.5**

### Why "Adjusted"?
Even **random** groupings agree on some pairs by luck, often more than half. So the plain score is never close to 0, even for nonsense.

The **adjusted** version subtracts what you'd expect by pure chance:
```
ARI = (actual agreement − agreement expected by chance)
      ÷ (perfect agreement − agreement expected by chance)
```
This gives a clean scale:
- **ARI = 1:** identical groupings
- **ARI ≈ 0:** no better than random
- In between: partial agreement

**Group names don't matter.** If the same genes are together but the group is now called "3" instead of "1", it still counts as a perfect match. Only **who is together with whom** matters.

For our real data, the computer does this with all **3,645 genes**, which is about **6.6 million pairs**.

## Part 2: How we got stability_ARI_mean (for one k, say k = 5)

**Step 1:** Cluster **all 3,645 genes** into 5 groups. This is the **original**.

**Step 2:** Randomly pick **80% of the genes** (about 2,900).

**Step 3:** Cluster **only those genes** into 5 groups again.

**Step 4:** Compare the new grouping with the original **for those same genes**, which gives one ARI score.

**Step 5:** Repeat Steps 2–4 **50 times**, with a different random 80% each time. That gives 50 ARI scores.

**Step 6:**
- **stability_ARI_mean** = the **average** of the 50 scores
- **stability_ARI_sd** = how much those 50 scores **varied**

Then we did all of this again for k = 3, 4, 6, 7 and 8.

## Your table, explained

| k | stability_ARI_mean | stability_ARI_sd | Meaning |
|---|---|---|---|
| 3 | 0.98 | 0.02 | almost identical every time |
| 4 | 0.97 | 0.03 | very stable |
| **5** | **0.96** | **0.03** | **very stable** ✅ |
| 6 | 0.93 | 0.06 | starting to wobble |
| 7 | 0.79 | 0.14 | unstable, big variation |
| 8 | 0.76 | 0.14 | unstable |

## The patient_bootstrap columns (E and F)
These use **the same ARI calculation**, but they shake the data differently:

| | What changes each time | Difficulty |
|---|---|---|
| **stability_ARI** (C, D) | which **genes** are included (80%) | easier test |
| **patient_bootstrap_ARI** (E, F) | which **patients** are used (resampled) | harder test |

Changing patients changes **every gene's pattern a little**, so it's tougher. That's why its scores are lower: **0.53 at k = 5**.

## In one sentence
> **ARI counts how many gene pairs stay "together" or "apart" between the original and a re-run, corrected for chance. We repeated the re-run 50 times and averaged the scores to get stability_ARI_mean.**


---

## then what is membership confidence...both are same?

then what is membership confidence...both are same?

No, they're **different**, though they're related. Both re-run the clustering on shaken-up data, but they answer **different questions**.

## The main difference

| | **ARI** (stability) | **Membership confidence** |
|---|---|---|
| **Question** | Is the **whole clustering** stable? | Is **this one gene** stable? |
| **Gives** | **one number for all genes together** | **one number per gene** |
| **Used for** | choosing k (3 to 8) | knowing which genes to trust |
| **Calculated for** | every k from 3 to 8 | only k = 5 (our final choice) |
| **Where** | `task2_choosing_k.csv` | `task2_gene_clusters.csv` |

## Simple analogy: a school with 5 classrooms
Every year students get reshuffled, and you want to know how stable the classes are.

**ARI is like asking:**
> "Overall, how similar are this year's classes to last year's?"

You get **one score for the whole school**, for example "the classes are 96% the same".

**Membership confidence is like asking, for each student:**
> "Over 100 years of reshuffling, how often was **Ravi** in Classroom 1?"

- Ravi: 85 of 100 times, so he clearly belongs in Classroom 1
- Priya: 38 of 100 times, so she keeps getting moved

You get **one score per student**.

## How each is calculated

### ARI (one score for the whole grouping)
```
Re-cluster → look at ALL gene PAIRS → how many stay together/apart?
→ ONE score for the whole clustering
Repeat 50× → average = stability_ARI_mean
```

### Membership confidence (one score per gene)
```
Re-cluster (resampling patients) → match new groups to original groups
→ for EACH gene: same group as before? yes/no
Repeat 100× → count the "yes" ÷ 100 = that gene's confidence
```

## How they connect
They tell **the same story** at two different levels.

- **patient_bootstrap_ARI at k = 5 = 0.53.** That's the **overall** score: "the whole clustering is only moderately stable when patients change".
- **Membership confidence** breaks that down and shows **which genes cause the instability**:

| Cluster | High-confidence genes |
|---|---|
| C2 Late increase | 56% of genes ✅ stable |
| C5 Late decrease | 61% of genes ✅ stable |
| C1 Early increase | 5% of genes ⚠️ mostly switching |
| C3 Early rise | 18% ⚠️ |
| C4 Mid decrease | 25% ⚠️ |

So the **0.53** is low **mainly because many C1, C3 and C4 genes move between groups**, while C2 and C5 are solid.

## In one sentence
> **ARI tells you how stable the clustering is overall (used to pick k). Membership confidence tells you how stable each individual gene is (used to decide which genes to trust).**


---

## then what is parent bootstrap

then what is parent bootstrap

I think you mean **patient bootstrap**, the column `patient_bootstrap_ARI`. It's about **patients**, not parents.

## What "bootstrap" means
**Bootstrap** is a way to **pretend we did the study again** without collecting new data.

**The idea:** if we had recruited a **different group of patients**, would we get the same result? We can't recruit new patients, so we **create a "new" group from the patients we already have**.

## How it works: drawing patients with replacement
Imagine all our patients' names are in a **bag**.
1. Pull out **one name** at random and write it down.
2. **Put it back in the bag.**
3. Pull again, and repeat until you have **as many names as you started with**.

Because names go back in the bag:
- **Some patients get picked twice** (or more)
- **Some patients get picked once**
- **Some patients don't get picked at all**

### Tiny example with 5 patients
```
Original:    P1, P2, P3, P4, P5
Bootstrap 1: P2, P2, P4, P5, P1    (P3 missing, P2 twice)
Bootstrap 2: P1, P3, P3, P3, P5    (P2 and P4 missing)
Bootstrap 3: P4, P1, P5, P2, P4    (P3 missing, P4 twice)
```
Each bootstrap is a **slightly different patient group**, like a new study would be.

## What we did with it in Task 2
We did the bag-drawing **separately within each study**, so each study keeps its size. Then, for each bootstrap:
1. **Recompute** every gene's F0–F4 pattern using the drawn patients.
2. **Re-cluster** the genes into groups.
3. **Compare** with the original clusters.

This gave two results:

| Result | What it is | Repeats |
|---|---|---|
| **patient_bootstrap_ARI** | **one score for the whole clustering**: how similar the new groups are to the original | 50 for each k (3 to 8) |
| **membership_confidence** | **one score per gene**: how often that gene stayed in its group | 100 at k = 5 |

So **patient bootstrap is the method** (shaking the patients), and ARI and membership confidence are **two ways of measuring** what happened.

## Patient bootstrap vs gene subsample
We used two different ways to shake the data:

| | **Gene subsample** | **Patient bootstrap** |
|---|---|---|
| What we change | leave out 20% of **genes** | redraw the **patients** |
| Gene patterns change? | ❌ no, same patterns | ✅ yes, every pattern shifts a little |
| Difficulty | easier test | **harder, more realistic test** |
| Score at k = 5 | 0.96 | 0.53 |

**Why is the patient bootstrap more realistic?** In real science, the question is "would **another study with different patients** find the same thing?" Resampling patients mimics exactly that.

## In one sentence
> **Patient bootstrap = randomly redrawing our own patients (with replacement) to simulate a new study, then checking whether the clusters come out the same.**


---

## then waht is the diff btw stability ari and bootstrap ari

then waht is the diff btw stability ari and bootstrap ari

They use the **same scoring method (ARI)** but **shake the data in different ways**.

## Same: how the score is calculated
Both compare **the new grouping** with **the original grouping** using ARI, by checking whether gene pairs stay together or apart.
- **1** = identical groups
- **0** = random

## Different: what we change before re-clustering

### stability_ARI: change the **genes**
```
Original data: 3,645 genes, all patients
      ↓
Randomly REMOVE 20% of genes   (patients untouched)
      ↓
Re-cluster the remaining 80%
      ↓
Compare with original → ARI
```
- Each gene's F0–F4 pattern is **exactly the same** as before.
- We only test whether the grouping **holds together when some genes are missing**.

### patient_bootstrap_ARI: change the **patients**
```
Original data: 3,645 genes, all patients
      ↓
Randomly REDRAW the patients   (all genes kept)
      ↓
Recompute every gene's F0–F4 pattern  ← patterns change!
      ↓
Re-cluster
      ↓
Compare with original → ARI
```
- Every gene's pattern **shifts a little**, because the patients are different.
- We test whether the grouping **holds up when the patients change**, like a new study.

## Side by side

| | **stability_ARI** | **patient_bootstrap_ARI** |
|---|---|---|
| What we change | **genes** (leave out 20%) | **patients** (redraw) |
| Do gene patterns change? | ❌ no | ✅ yes |
| Question answered | "Is the grouping consistent?" | "Would a **new study** find the same groups?" |
| Difficulty | easier | **harder** |
| Score at k = 5 | **0.96** | **0.53** |
| Used for | choosing k | checking how realistic the clusters are |

## Simple analogy: sorting fruit into baskets
**stability_ARI:** take away 20% of the fruits and sort the rest again.
> The fruits look **the same**, so you'll sort them almost the same way. **High score.**

**patient_bootstrap_ARI:** look at the **same kinds of fruit, but from a different harvest**. Each apple looks a bit different this time.
> Fruits that are **clearly** apples or clearly oranges still go in the right basket. But a fruit that's **half-way between** may land in a different basket this time. **Lower score.**

## What the two results tell us together
- **High stability_ARI (0.96):** the clustering method itself is **consistent and well-defined**.
- **Lower bootstrap ARI (0.53):** with different patients, **borderline genes move** between neighbouring groups.
- But the **5 shapes still come back** every time (match 0.97–0.997).

So:
> ✅ **The patterns are real.**
> ⚠️ **Exactly which borderline genes belong to which pattern is less certain.** That's why we use membership_confidence.


---

## what is this

what is this


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\14.png]

This is **`task2_robustness.csv`**. It's a summary of **3 safety checks** on the Task 2 clusters. Widen column A to see the full names:

| Check | Value |
|---|---|
| study-adjusted profiles: ARI vs main clusters | **0.844** |
| study-adjusted profiles: median per-gene curve correlation | **0.998** |
| patient bootstrap ARI at chosen k=5 (mean) | **0.526** |

## The worry behind the first two checks
Our patients come from **5 different studies**, and each study has a **different mix of stages**:

| Study | F0 | F1 | F2 | F3 | F4 |
|---|---|---|---|---|---|
| GSE193066 | 6 | 45 | **71** | 41 | **1** |
| GSE162694 | **66** | 30 | 27 | 8 | 12 |

So the **F2 average** is mostly GSE193066 patients, and the **F0 average** is mostly GSE162694 patients. If those two studies measure genes slightly differently, a gene's pattern could **look like it changes with stage when it's really just changing between studies**.

## How we checked: "study-adjusted" patterns
We rebuilt every gene's F0–F4 pattern **with a correction for study**, using a model:
```
gene level = stage effect + study effect
```
This separates out the study differences, so the **stage effect** shows only the **real stage change**. Then we compared these corrected patterns with our original ones.

## Row 2: Do the gene patterns change? (0.998)
For each gene, we compared its **original pattern** with its **study-adjusted pattern** (correlation, where 1 = identical shape).
> **Median = 0.998, so the patterns are almost perfectly identical.** ✅

The study mix **did not distort** the patterns.

## Row 1: Do the clusters change? (0.844)
We **re-clustered** the study-adjusted patterns into 5 groups and compared them with the original clusters using ARI.
> **ARI = 0.844, so the clusters mostly match.** ✅

Why not 1.0? A few **borderline genes** moved. For example, 123 genes moved between C1 and C2, which are both "rising" and differ only in timing. Every cluster still maps clearly onto the same pattern. (The details are in `task2_robustness_crosstab.csv`.)

## Row 3: Patient bootstrap ARI (0.526)
This is the **same number** we discussed before, copied here so all the checks are in one place:
> When we **redraw the patients**, the overall cluster agreement is **0.53**. The **shapes** stay solid, but **borderline genes switch** groups.

## What the whole file says

| Check | Result | Conclusion |
|---|---|---|
| Does study mix distort the patterns? | 0.998 | ✅ No |
| Do clusters survive study correction? | 0.844 | ✅ Yes, mostly |
| Do clusters survive new patients? | 0.526 | ⚠️ Shapes yes, borderline genes move |

> **The 5 patterns are real and not caused by study differences. Individual borderline genes are less certain, so use high-confidence genes when naming specific genes.**


---

## At which transition does the largest molecular change occur: F0→F1, F1→F2, F2→F3, or F3→F4

At which transition does the largest molecular change occur: F0→F1, F1→F2, F2→F3, or F3→F4?
Do not rely only on differences of stage means. Where sample-level data permit, perform appropriate statistical comparisons as well.
what statistical comparisions we performed?

We did **4 statistical comparisons**. Here's each one, simply, with its proper name so you can use it in the paper's methods.

## 1. Linear regression with a study adjustment (the main test)
**What:** for **each gene** and **each step** (F0→F1, F1→F2, F2→F3, F3→F4), we compared the **actual patients** in the two stages.

**How:** a linear model, run 3,645 genes × 4 steps = **14,580 times**:
```
gene expression = stage + study
```
- **stage:** is this patient in the earlier or the later stage?
- **study:** which of the 5 studies the patient came from

**Why include study?** So stages are compared **within the same study**, and differences between labs can't fake a stage effect.

**Result for each gene:**
- **β (beta):** **how much** the gene changes between the two stages
- **t-test on β:** a **p-value** for whether that change is real or chance

**Patient handling before the test:**
- **Each patient counted once.** Repeat biopsies at the same stage were averaged (28 patients).
- **Patients biopsied on both sides of a step:** one sample kept, chosen at random (24 patients).
- **Only studies with patients in both stages** were used for that step.

> **Paper name:** *"Ordinary least-squares linear regression of expression on stage, adjusted for study as a fixed effect; significance by t-test on the stage coefficient."*

## 2. Multiple-testing correction (BH-FDR)
**What:** we ran 3,645 tests per step, so some would look significant by luck.

**How:** the **Benjamini–Hochberg** correction turns each p-value into a **q-value**. A gene is significant if **q < 0.05**.

A gene counts as **"substantially changing"** if **both**:
- **q < 0.05** (statistically real), **and**
- **|β| ≥ 0.2** (the change is big enough to matter)

> **Paper name:** *"Benjamini–Hochberg FDR within each transition; substantial change defined as FDR < 0.05 and |β| ≥ 0.2 SD."*

## 3. Power-matched subsampling (fairness test)
**Problem:** F4 has only **34 patients**, versus 109–166 in other stages. Fewer patients make it **harder to reach significance**, so F3→F4 would look weaker even if its changes were bigger.

**How:**
- For **every** step, randomly pick **the same number of patients**: 30 per stage, **balanced by study** (2 + 14 + 8 + 6).
- Run **tests 1 and 2 again** on these equal-sized groups.
- **Repeat 50 times**, and report the median.

**Result:**
| | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Significant genes (median) | 0 | 0 | 2 | **311** |

> **Paper name:** *"Power-matched, study-balanced subsampling (n = 30 per stage, 50 repetitions)."*

## 4. Effect-size comparison (doesn't depend on patient numbers)
**What:** instead of counting significant genes, compare **how big** the changes are.

**How:** take the **median |β|** across all 3,645 genes for each step, and count genes with |β| ≥ 0.2.

| | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Median change size | 0.19 | 0.19 | 0.22 | **0.38** |
| Genes with change ≥ 0.2 | 1,699 | 1,693 | 2,043 | **2,710** |

> **Paper name:** *"Distribution of study-adjusted effect sizes (median |β|) per transition."*

## Plus: the simple comparison (difference of stage means)
We **also** calculated the simple version (next stage average minus this stage average), as the mentor asked. But we **didn't rely only on it**, which is exactly what tests 1–4 add.

## Summary

| # | Test | Question it answers |
|---|---|---|
| — | Difference of stage means | Rough change per step |
| 1 | Linear regression + study adjustment + t-test | Is each gene's change **real**? |
| 2 | BH-FDR correction | Which changes survive **many tests**? |
| 3 | Power-matched subsampling | Which step wins with **equal patients**? |
| 4 | Effect-size comparison | Which step has the **biggest** changes? |

**All of them point to the same answer: F3→F4.**


---

## i didnt understand.explain clearly in simple words

i didnt understand.explain clearly in simple words

Sorry, that was too much at once. Let me explain it very simply, with one example.

## The question
Between two stages, for example F3 and F4, **did a gene really change, or did it just look like it changed by luck?**

## The simple way (averages) and its problem
Say the average level of a gene is:
- F3 patients: **0.21**
- F4 patients: **0.28**

It looks like it went up. **But is that real?**

Imagine measuring **the height of students** in two classes:
- Class A average: 160 cm
- Class B average: 162 cm

Is class B really taller? **It depends:**
- If heights in each class vary a lot (some 140, some 180), a 2 cm difference could easily be **luck**.
- If everyone's height is very similar, a 2 cm difference is probably **real**.

**Averages alone can't tell you this.** That's why your mentor said not to rely only on averages.

## What we did instead: a statistical test
We looked at **every single patient**, not just the averages.

For each gene and each step (like F3 → F4), the test looks at:
1. **How big** the difference between the two stages is
2. **How much patients vary** within each stage
3. **How many patients** there are

Then it gives a **p-value**:
> **"What's the chance this difference is just luck?"**
- small p-value → **real change** ✅
- large p-value → **could be luck** ❌

We did this for **every gene** at **every step**.

## Two things we made sure of to keep it fair

### Fairness 1: Different studies
Patients came from **5 different labs**. Each lab measures slightly differently, like **5 different weighing scales**, some reading a bit heavier.

So we **only compared patients from the same lab with each other**. That way, lab differences can't fool us.

### Fairness 2: Each patient counted once
Some patients had **two biopsies**. We made sure **each person counted only once**.

## Then we counted
For each step, we counted **how many genes really changed**: a small p-value **and** a big enough change.

## One more fairness check
F4 has **only 34 patients**, while the other stages have 109–166.
**Fewer people makes it harder to prove anything**, like judging a class from 34 students instead of 160.

So we gave **every step the same 30 patients per stage** and tested again:

| Step | F0→F1 | F1→F2 | F2→F3 | **F3→F4** |
|---|---|---|---|---|
| Genes that really changed | 0 | 0 | 2 | **311** |

**With a fair comparison, F3→F4 clearly wins.**

We also checked **how big** the changes were, and F3→F4 changes were about **twice as big** as at the other steps.

## The answer
> **The biggest change in the liver happens at F3 → F4, the step into cirrhosis.**

## In 3 lines
1. **Averages can lie**, so we tested every patient to check whether each change is **real or luck**.
2. We kept it **fair**: compared within the same lab, counted each patient once, and used equal patient numbers.
3. **All the checks say the same thing: F3 → F4 has the biggest change.**


---

## u are telling each study we did seperately...how we calculayted the change?

u are telling each study we did seperately...how we calculayted the change?

Good question. Let me be clear: we did **not** run a completely separate analysis per study. We ran **one test per gene**, built so that it **compares patients only within the same study** and then **combines** those comparisons.

Here's exactly how the change is calculated.

## A simple example: one gene, step F3 → F4, two studies

### Study A
| | Patients | Average level |
|---|---|---|
| F3 | 10 | 0.10 |
| F4 | 10 | 0.50 |

**Change inside Study A = 0.50 − 0.10 = +0.40**

### Study B
| | Patients | Average level |
|---|---|---|
| F3 | 20 | -0.30 |
| F4 | 5 | 0.00 |

**Change inside Study B = 0.00 − (-0.30) = +0.30**

### Combine them
We take an **average of the two changes**. Studies with **more patients in both stages** count more, because their result is more reliable.
```
Study A change = +0.40   (10 vs 10 patients → strong weight)
Study B change = +0.30   (20 vs 5 patients  → a bit weaker weight)

Combined change (β) ≈ +0.36
```
**β is the final "change" for this gene at this step.**

## Why not just pool everyone together?
If we ignored studies and pooled all patients:

| | All F3 patients | All F4 patients |
|---|---|---|
| Patients | 10 (A) + 20 (B) = 30 | 10 (A) + 5 (B) = 15 |
| Average | (10×0.10 + 20×(−0.30)) ÷ 30 = **−0.17** | (10×0.50 + 5×0.00) ÷ 15 = **0.33** |

**Pooled change = 0.33 − (−0.17) = +0.50** ❌

That's **wrong**: the real change in each study was only +0.30 to +0.40.

**Why?** Study B's patients read lower overall (−0.30 vs 0.10), like a scale that reads light. Study B makes up most of the F3 group but only a small part of F4. So **"which study the patient came from" got mixed up with "which stage they're in"**, and that inflated the change.

Comparing **within each study first** avoids this.

## What the computer actually did
The model **`expression = stage + study`** does exactly this automatically:
- The **"study" part** absorbs the difference between labs (Study B reading lower).
- The **"stage" part** is what's left: the **change between stages within the same study**, combined across all studies. That's **β**.

Then, for each gene, it also asks whether β is **real or luck** (the p-value), based on how much patients vary and how many there are.

We did this:
- for **every gene** (3,645)
- at **every step** (4 steps)
- using **all studies that had patients in both stages** (all 5 for every step)

## Summary
```
1. Inside each study:   change = later stage − earlier stage
2. Combine studies:     weighted average → β (the final change)
3. Test:                is β real or luck? → p-value → q-value
```

> **We measured the change inside each study, so lab differences can't fake it, then combined all studies into one change per gene per step.**


---

## what do each column represent

what do each column represent


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\15.png]

This is **`task3_all_genes_all_transitions.csv`**, the **full results** for Task 3. **Each row = one gene at one step.** There are 3,645 genes × 4 steps = **14,580 rows**.

First, the strange **"F0â†'F1"** you see is a display problem: Excel isn't reading the **→** arrow correctly. It means **F0→F1**. I'll fix that in the files right after this.

## Each column, using FGR (row 2) as the example

| Column | Meaning | FGR |
|---|---|---|
| **ensembl_id** | the gene's official ID code | ENSG000… |
| **symbol** | the gene's name | FGR |
| **transition** | which step is being tested | F0→F1 |
| **delta_mean** | **simple change** = F1 average − F0 average (the "averages only" method) | 0.364 |
| **beta_adjusted** | **proper change** from the patient-level test, compared within each study (this is the β we discussed) | 0.489 |
| **se** | **standard error**: how uncertain β is (smaller = more precise) | 0.112 |
| **p_value** | chance the change is just luck, for this one gene | very small (cut off in Excel) |
| **q_value** | p-value **corrected** for testing thousands of genes (BH-FDR) | 0.0006 |
| **n_patients** | patients used in this test (F0 + F1 patients) | 318 |
| **substantial** | **TRUE** if q < 0.05 **and** \|β\| ≥ 0.2, meaning a real and big change | TRUE ✅ |
| **cluster** | which Task 2 group the gene belongs to | 3 |
| **cluster_name** | that group's shape | Early rise, then plateau |

## Reading a few rows

**FGR at F0→F1:**
- Change β = **+0.49**, so it goes **up**
- q = **0.0006**, far below 0.05, so **real**
- Substantial = **TRUE** ✅
- It's in cluster 3 ("early rise"), which fits: it rises **early**

**GCLC at F0→F1:**
- Change β = **+0.01**, almost zero
- q = **0.93**, much bigger than 0.05, so **no real change**
- Substantial = **FALSE**
- It's in cluster 5 ("late decrease"), which fits: it **doesn't change early**, it falls **late**

**LASP1 at F0→F1:**
- β = **+0.37**, q = **0.008**, so **TRUE** ✅
- Cluster 1 ("early increase"), which fits

So the **clusters from Task 2 agree with the tests in Task 3**: early-cluster genes change early, and late-cluster genes don't.

## delta_mean vs beta_adjusted: why two "change" columns?

| | **delta_mean** | **beta_adjusted** |
|---|---|---|
| Method | simple average difference | patient-level test, within each study |
| Corrects for lab differences? | ❌ no | ✅ yes |
| Has a p-value? | ❌ no | ✅ yes |
| Used for the final answer? | shown for comparison | ✅ **yes** |

They're usually **similar** (FGR: 0.36 vs 0.49), but **beta_adjusted is the trustworthy one**.

## Quick rules for reading it
- **beta_adjusted positive:** the gene goes **up** at that step
- **beta_adjusted negative:** the gene goes **down**
- **q_value < 0.05:** the change is **real**
- **substantial = TRUE:** the change is real **and** big enough to count

Now fixing the arrow display:


<sub>ran — Bash: Find all CSV writes in the task scripts · Bash: Make CSVs Excel-friendly UTF-8 and update scripts</sub>

That file is **open in Excel right now**, which locks it, so I can't change it. I'll fix all the other files and list any that are locked:


<sub>ran — Bash: Re-encode unlocked CSVs, list locked ones</sub>

The arrow fix is done for **71 of the 72 CSV files**:
- The fix makes Excel read **F0→F1** correctly instead of "F0â†'F1".
- I also updated the 4 scripts, so any future re-run saves the files the same way.

**One file is left:** `task3_all_genes_all_transitions.csv`, the one you have open. Excel locks a file while it's open, so I couldn't change it.

**What to do:** close that file in Excel, without saving, then tell me **"done"** and I'll fix it in a second.

Also, the zip I sent earlier still has the old files. Once this last one is fixed, I'll make a **new zip** for you to send.


---

## explain se, p_value, q-value

explain se, p_value, q-value

Here are all three, using **two real genes** from your file at the **F0→F1** step.

| Gene | beta (change) | se | p_value | q_value |
|---|---|---|---|---|
| **FGR** | 0.489 | 0.112 | 0.000019 | 0.0006 |
| **GCLC** | 0.015 | 0.110 | 0.894 | 0.933 |

## 1. se: Standard Error, "how uncertain is the change?"
**beta** is our **best guess** of how much the gene changed. But it's measured from a sample of patients, so it's not perfectly exact. **se** says **how far off** that guess might be.

- **Small se:** the guess is **precise**
- **Large se:** the guess is **wobbly**

**Simple analogy:** you weigh yourself on a scale that reads 60 kg.
- On a good scale it's ±0.1 kg (small se) and you can trust it.
- On a cheap scale it's ±5 kg (large se) and you're not sure.

**For FGR:** change = 0.489, se = 0.112. The real change is roughly **0.49 ± 0.22**, somewhere between **0.27 and 0.71**. That whole range is **above 0**, so it **really went up**.

**For GCLC:** change = 0.015, se = 0.110. The real change is roughly **0.015 ± 0.22**, between **-0.20 and +0.23**. That range **includes 0**, so it **might not have changed at all**.

The rule of thumb is **change ÷ se**:
- FGR: 0.489 ÷ 0.112 = **4.4**, much bigger than the uncertainty → real ✅
- GCLC: 0.015 ÷ 0.110 = **0.1**, smaller than the uncertainty → could be nothing ❌

## 2. p_value: "could this change be just luck?"
The p-value turns **change ÷ se** into a probability:
> **"If the gene truly didn't change at all, how likely is it to see a change this big just by chance?"**

- **FGR: p = 0.000019**, which is about **2 in 100,000**. Very unlikely to be luck, so **real** ✅
- **GCLC: p = 0.894**, which is **89%**. Very likely luck, so **not real** ❌

**Rule:** smaller p = more convincing.

In Excel, FGR's p shows as "1.8817337", but that's cut off. The real value is **1.88 × 10⁻⁵** = 0.0000188.

## 3. q_value: "p-value corrected for testing thousands of genes"
**The problem:** we tested **3,645 genes** at this step. Even if no gene truly changed, about **5% would get p < 0.05 by pure luck**, which is around **180 fake hits**.

**The fix:** **BH-FDR correction** adjusts each p-value upward to account for running so many tests. The adjusted value is the **q-value**.

- **FGR:** p = 0.000019 → **q = 0.0006**, still tiny, so **real** ✅
- **GCLC:** p = 0.894 → **q = 0.933**, so **not real** ❌

**Rule:**
> **q < 0.05 → we call it significant.**
> Among all genes we call significant, at most 5% are expected to be false.

## How the three fit together

```
beta  = how much the gene changed          (0.489)
  ÷
se    = how uncertain that is               (0.112)
  ↓
p     = chance it's luck, for one gene      (0.000019)
  ↓
q     = p corrected for 3,645 genes         (0.0006)
  ↓
q < 0.05  AND  |beta| ≥ 0.2  →  substantial = TRUE
```

## In one line each
- **se:** how **precise** the change estimate is
- **p_value:** how likely the change is **just luck**, for one gene
- **q_value:** the same, but **corrected for testing many genes**. This is the one we use to decide.


---

## once tell this

once tell this


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\16.png]


<sub>ran — Bash: Retry fixing the previously locked CSV · PowerShell: Rebuild the zip with fixed CSVs</sub>

The new zip failed because the file you have open is locked, and that also removed the old zip. I'll rebuild it with Python, which can still read open files:


<sub>ran — Bash: Rebuild the results zip with Python</sub>

All the CSV files now show the arrows correctly, and a **new zip** is ready: `Paper1_Results.zip` (12.5 MB) in the same place. **Use this one, not the old one.**

Now, your table. This is **`task3_cluster_by_transition.csv`**, which connects **Task 2 (clusters)** with **Task 3 (patient tests)**. It asks:
> **"For each cluster, at which step do its genes really change?"**

## The columns

| Column | Meaning |
|---|---|
| **cluster / cluster_name** | which Task 2 group |
| **transition** | which step |
| **median_beta** | the **typical change** for genes in this cluster at this step (positive = up, negative = down) |
| **n_sig_up** | how many genes in this cluster **significantly went up** at this step (q < 0.05) |
| **n_sig_down** | how many **significantly went down** |
| **n_genes** | total genes in the cluster |

## Reading each cluster

### C1: Early increase (927 genes)
| Step | Typical change | Significantly up |
|---|---|---|
| **F0→F1** | **+0.33** | **679** ✅ biggest |
| F1→F2 | +0.16 | 201 |
| F2→F3 | +0.18 | 193 |
| F3→F4 | +0.31 | 55 |

**Biggest jump at F0→F1**, so it really rises **early**. ✅ Matches its name.

### C2: Late increase (1,514 genes)
| Step | Typical change | Significantly up |
|---|---|---|
| F0→F1 | +0.15 | 287 |
| F1→F2 | +0.16 | 412 |
| F2→F3 | +0.28 | 693 |
| **F3→F4** | **+0.60** | **809** ✅ biggest |

Gets **bigger and bigger**, with the biggest jump at **F3→F4**. ✅ Truly **late**.

### C3: Early rise, then plateau (197 genes)
| Step | Typical change | Significantly up |
|---|---|---|
| **F0→F1** | **+0.32** | **138** ✅ |
| F1→F2 | +0.16 | 41 |
| F2→F3 | +0.14 | 20 |
| F3→F4 | **-0.04** | **0** |

Rises **early**, then gets weaker and weaker, and at F3→F4 there's **no change at all** (0 genes). ✅ This is why we renamed it from "rise then fall" to **"rise, then plateau"**: the "fall" at F4 wasn't real.

### C4: Mid decrease (309 genes)
| Step | Typical change | Significantly down |
|---|---|---|
| F0→F1 | +0.01 | 16 |
| **F1→F2** | **-0.27** | **185** ✅ biggest |
| F2→F3 | -0.17 | 47 |
| F3→F4 | +0.04 | 0 |

Nothing early, then a **big drop at F1→F2**, and it **stops falling** by F4. ✅ **Mid** decrease.

### C5: Late decrease (698 genes)
(Only the first two rows are visible in your screenshot.)
| Step | Typical change | Significantly down |
|---|---|---|
| F0→F1 | +0.04 | 14 |
| F1→F2 | -0.25 | 342 |
| F2→F3 | -0.21 | 164 |
| **F3→F4** | **-0.28** | 71 |

It keeps falling from F1 onwards, and the typical drop is **largest at F3→F4**. Fewer genes reach significance there only because **F4 has just 34 patients**.

## Why this table matters
In Task 2, the clusters were made from **averages only**. This table **checks them with real patient-level statistics**:

| Cluster | Name from Task 2 | Confirmed by patient tests? |
|---|---|---|
| C1 | Early increase | ✅ yes, biggest change at F0→F1 |
| C2 | Late increase | ✅ yes, biggest at F3→F4 |
| C3 | Early rise, plateau | ✅ yes, and showed the F4 "drop" was not real |
| C4 | Mid decrease | ✅ yes, biggest at F1→F2 |
| C5 | Late decrease | ✅ yes, largest typical drop at F3→F4 |

> **The clusters from Task 2 hold up when tested on real patients. Each group changes exactly where its name says.**

Here's Task 4 again, as simply as I can: **what** we did, then **how**, then **what we found**.

## What we did, in one sentence
> We took each list of genes and asked: **"What jobs do these genes do in the body?"**

A list of names like *COL1A1, LOXL1, FBN1…* means nothing on its own. But if most of them are **scar-making genes**, then we know the list is about **making scar tissue**. That's enrichment.

## How we did it: 5 steps

### Step 1: Split the genes into separate lists
We did **not** put all 4,692 genes in one pile, because rising and falling genes do opposite things and would blur together. We made **11 lists**:
- **6 lists from Task 1:** fibrosis-only (up / down), inflammation-only (up / down), shared (up / down)
- **5 lists from Task 2:** clusters C1, C2, C3, C4 and C5

### Step 2: Get 4 "job dictionaries"
Scientists have already sorted genes into **pathways**, groups of genes that do the same job. We used 4 well-known collections:

| Dictionary | Like… |
|---|---|
| **GO Biological Process** | a very detailed dictionary |
| **KEGG** | a classic textbook |
| **Reactome** | a step-by-step manual |
| **Hallmark** | a short summary of 50 big themes |

### Step 3: Count and compare
For each list and each pathway, we asked:
> **"Are there more genes from this pathway in our list than we'd expect by chance?"**

**Real example:**
- List: **shared rising genes** (1,335 genes)
- Pathway: **scar formation (EMT)**
- **By chance** we'd expect about **17** scar genes in the list.
- **We actually found 77.**
- 77 is about **4.5× more than chance**, so this list is **strongly about scar formation**.

### Step 4: Compare against the right genes (the mentor's main point)
To work out "expected by chance", you need to know **what you're comparing against**:
- ❌ **Most tools** compare against **all ~20,000 human genes**.
- ✅ **We compared against only the 14,794 genes we actually tested.**

**Why?** About 5,000 genes were never measured, so they had **zero chance** of being in our lists. Counting them would make our results look **better than they really are**.

**Simple example:** 5 of the 10 students you picked wear glasses. Is that unusual? Compare with **their own classroom**, not the whole school.

### Step 5: Keep only trustworthy results
We tested thousands of pathways, so some would look good **by luck**. We used the **BH-FDR < 0.05** correction to remove those, and kept only pathways that pass.

For each kept pathway we saved:
- **how many** of our genes are in it (gene count)
- the **gene ratio**: our genes in the pathway ÷ the size of our list
- **which genes** caused it, for example COL1A1, LOXL1…

## What we found

| Gene list | What these genes do |
|---|---|
| Fibrosis-only, rising | 🛡️ **Immune system activation** |
| Fibrosis-only, falling | 🍽️ **Normal liver work**: processing fat, bile and drugs |
| Inflammation-only | Very weak signal |
| Shared, rising | 🧱 **Making scar tissue** (collagen) |
| Shared, falling | 🍽️ Normal liver metabolism |
| C1 (early rise) | 🛡️ Immune activation, starting **early** |
| C2 (late rise) | 🧱 Scar tissue, speeding up **late** |
| C3 (early rise, plateau) | 🔄 **Cells dividing** |
| C4 (mid drop) | No clear job |
| C5 (late drop) | 🍽️ Liver metabolism **failing** at cirrhosis |

## The story it tells
```
EARLY (F0→F1):  immune system switches on     (C1)
                cells start dividing           (C3)
        ↓
LATE (F3→F4):   scar tissue builds up fast     (C2)
                normal liver work shuts down   (C5)
```
> **Liver fibrosis starts with immune activation and ends with heavy scarring and loss of normal liver function, with the biggest change at the step into cirrhosis.**

## What you'll find in the Task4 folder
- **64 tables:** 16 gene lists (the 11 above plus 5 cluster checks) × 4 dictionaries, each with its own CSV
- **Dot plots:** a picture of the top jobs for each list
- **4 heatmaps:** one per dictionary, comparing all lists side by side


---

## explain step 4 and 5 clearly...i didnt understand

explain step 4 and 5 clearly...i didnt understand

Let me use **one real example** for both steps: the **scar formation (EMT)** pathway in the **shared rising genes**.

# Step 4: Comparing against the right genes

## The basic question
We found **77 scar-formation genes** in our list of 1,335 genes. Is 77 a lot? To know, we need to work out **how many we'd expect by pure chance**, and that depends on **what we compare against**.

## The bag-of-balls idea
Imagine a **bag of balls**:
- Each ball is **one gene**.
- **Red balls** are scar-formation genes; **white balls** are all other genes.

Our list is like **grabbing 1,335 balls** from the bag. If we grab randomly, how many red balls would we expect? That depends on **what's in the bag**.

### ❌ Wrong bag: all human genes
| | |
|---|---|
| Balls in the bag | **20,000** (all human genes) |
| Red balls (scar genes) | 200 |
| Red share | 200 ÷ 20,000 = **1.0%** |
| Expected red in 1,335 grabs | 1,335 × 1.0% = **13** |
| We found | 77 |
| **77 ÷ 13** | **5.8× more than chance** |

### ✅ Right bag: only the genes we actually tested
| | |
|---|---|
| Balls in the bag | **14,794** (genes we tested) |
| Red balls (scar genes we tested) | 190 |
| Red share | 190 ÷ 14,794 = **1.3%** |
| Expected red in 1,335 grabs | 1,335 × 1.3% = **17** |
| We found | 77 |
| **77 ÷ 17** | **4.5× more than chance** |

## Why the right bag matters
About **5,000 human genes were never measured** in our studies. Those genes **could never appear in our list**, no matter what. So **putting them in the bag is unfair**:
- It makes the bag bigger, so the **expected number goes down** (13 instead of 17).
- So our result **looks more impressive** (5.8× instead of 4.5×).

That's **cheating without meaning to**. Your mentor wanted the **honest** version, so we used the **right bag**: the 14,794 tested genes.

**One-line analogy:** you can only pick students from **your own classroom**, so compare with **your classroom**, not the whole school.

## How we made sure the right bag was used
- We **removed** untested genes from every pathway **before** testing (that's why EMT counts as 190 genes, not 200).
- We ran the test **on our own computer**, because many websites quietly use all 20,000 genes.
- We **checked one result by hand**, and it matched exactly.

# Step 5: Keeping only trustworthy results

## The problem: we tested thousands of pathways
For each gene list, we didn't test just EMT. We tested **thousands of pathways**: about 4,800 GO + 180 KEGG + 1,300 Reactome + 50 Hallmark.

When you test that many, **some will look good just by luck**.

**Lottery analogy:** if **one** person wins the lottery, that's surprising. But if **a million** people play, **someone** will win. Not because they're special, just because so many played.

In the same way, among thousands of pathways, a few will look "enriched" **by pure luck**.

## The fix: BH-FDR correction
For every pathway, the test gives a **p-value**, the chance the result is luck. Then the **BH-FDR correction** makes each p-value **stricter**, to account for testing so many pathways. The corrected number is the **q-value**.

**Rule:**
> **q < 0.05 → keep it** ✅ (real)
> **q ≥ 0.05 → throw it away** ❌ (could be luck)

This guarantees that **among all the pathways we keep, at most 5% are expected to be luck**.

**For EMT:** q is so tiny that the computer shows 0. **Definitely real.** ✅

## What we saved for each pathway we kept
Your mentor asked us to keep the details, so for each pathway we saved:

| Column | Meaning | EMT example |
|---|---|---|
| **overlap** | how many of our genes are in this pathway | **77** |
| **set_size** | how big the pathway is (in our tested genes) | 190 |
| **gene_ratio** | 77 ÷ 1,335 (our list size) | **0.058** (5.8% of our list) |
| **fold_enrichment** | how many times more than chance | **4.5×** |
| **q_value** | the corrected chance it's luck | ≈ 0 |
| **genes** | **which genes** caused it | COL1A1, COL1A2, LOXL1, FBN1, TIMP1… |

The **genes column** is important: it lets anyone check **exactly which genes** are behind each result.

# Both steps in 3 lines
1. **Step 4:** to judge whether 77 is "a lot", compare against **only the genes we tested** (14,794), not all human genes. Otherwise results look better than they are.
2. **Step 5:** we tested thousands of pathways, so we **removed lucky results** using the FDR correction, keeping only q < 0.05.
3. For each pathway we kept, we saved **how many genes, what ratio, and which genes**.


---

## so these pathways not only related to liver right?

so these pathways not only related to liver right?

Right. **These pathways are general. They're not specific to the liver.** The databases describe biology in the **whole human body**, built from research on many tissues, diseases and cell types.

## Why some pathway names look strange
You may have noticed results like:

| Pathway name | Sounds like… | What it really means here |
|---|---|---|
| **Allograft rejection** | organ transplant rejection | **immune cells (T cells) attacking tissue**, the same immune process as in liver inflammation |
| **Small cell lung cancer** | lung cancer | genes for **cell growth and survival** that also appear in lung cancer |
| **Leishmania infection** | a parasite disease | **immune response genes** (inflammation, macrophages) |
| **Epithelial–mesenchymal transition** | first studied in cancer and development | cells changing into **scar-forming cells**, central to fibrosis |
| **Pathways in cancer** | cancer | **growth signals** shared by many diseases |

The **name** comes from **where the pathway was first studied**. The **genes inside** do a general job that happens in many tissues.

**Example:** "Allograft rejection" is a set of **immune genes**. They switch on when a transplant is rejected, **and also** when the liver is inflamed. Our finding doesn't mean the liver is being rejected. It means **the same immune genes are active**.

## So how should we read the results?
Think of the pathway as **the type of job**, not the place:
- ✅ "Our fibrosis genes are rich in **immune activation** genes"
- ❌ "Our fibrosis genes show allograft rejection"

And because **our genes come from liver biopsies**, the context is the liver:
> The pathways tell us **what kind of process** is happening. The data tells us **it's happening in the diseased liver**.

## Some pathways do fit the liver directly
Many of the results are **classic liver biology**:

| Pathway | Why it's a liver job |
|---|---|
| **Bile acid metabolism** | the liver makes bile |
| **Fatty acid metabolism** | the liver processes fat |
| **Xenobiotic / drug metabolism (cytochrome P450)** | the liver breaks down drugs and toxins |
| **Coagulation / complement** | the liver makes blood-clotting proteins |
| **Collagen formation / ECM** | scar tissue, the hallmark of liver fibrosis |

These falling (or rising) in our data make **direct biological sense** for liver disease.

## Tip for writing the paper
When you describe results, **use the biological process, not the odd name**:

| Instead of… | Write… |
|---|---|
| "Allograft rejection was enriched" | "Immune/T-cell activation genes were enriched (e.g., Hallmark allograft rejection)" |
| "Small cell lung cancer pathway" | "Cell growth and survival signalling" |
| "Leishmania infection" | "Innate immune / macrophage response" |

Reviewers know these names are general, but explaining them this way shows **you understand what the result means**.

## In one sentence
> **The pathways are general human biology, not liver-specific. They tell us what kind of job our genes do, and because our genes come from diseased livers, we interpret those jobs in the context of liver fibrosis.**


---

## how we selected the top pathways for each group

how we selected the top pathways for each group


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\17.png]

This is **`task4_top_pathways_per_group.csv`**.

## The rule
For **each gene list** and **each database**:
1. **Keep only significant pathways** (q < 0.05).
2. **Sort them by p-value**, smallest first (the most convincing at the top).
3. **Take the top 10.**

So each group gets up to **10 top pathways from each of the 4 databases**.

Your screenshot shows **fibrosis-only rising genes (1,301 genes)** in **GO**, sorted from most to least convincing.

## Reading the first row
| Column | Value | Meaning |
|---|---|---|
| **term_label** | Myeloid leukocyte activation | the job: activating immune cells |
| **overlap** | 50 | 50 of our genes are in this pathway |
| **set_size** | 212 | the pathway has 212 genes (among the genes we tested) |
| **n_group_genes** | 1,301 | size of our list |
| **gene_ratio** | 0.0384 | 50 ÷ 1,301, so 3.8% of our list |
| **bg_ratio** | 0.0143 | 212 ÷ 14,794, so 1.4% of all tested genes |
| **fold_enrichment** | 2.68 | 3.8% ÷ 1.4%, so **2.7× more than chance** |
| **p_value** | 6.5 × 10⁻¹¹ | chance it's luck: extremely small |
| **q_value** | 2.8 × 10⁻⁷ | after correction: still extremely small |
| **genes** | PIK3CD, SYK, … | the 50 genes responsible |
| **significant** | TRUE | q < 0.05 ✅ |

The p_value and q_value cells look like "6.4782843" because Excel is cutting them off. They're really tiny numbers like 6.5 × 10⁻¹¹. Click a cell and look at the formula bar to see the full value.

## Why sort by p-value and not fold enrichment?
Look at **rows 2 and 6**:

| Row | Pathway | Overlap | Fold | p-value |
|---|---|---|---|---|
| 2 | Myeloid leukocyte activation | **50** | 2.7× | 6.5 × 10⁻¹¹ |
| 6 | Myeloid cell activation (immune response) | **26** | **3.4×** | 1.1 × 10⁻⁹ |

Row 6 has a **higher fold** (3.4×) but ranks **lower**. Why?

The **p-value considers two things together**:
1. **How much more than chance** (fold)
2. **How many genes** support it (overlap)

**Simple analogy:**
- A student who scores **9/10** on a 10-question quiz
- A student who scores **45/50** on a 50-question test

Both got 90%, but the **second is more convincing**, because they answered far more questions.

In the same way, **50 genes at 2.7×** is stronger evidence than **26 genes at 3.4×**. The p-value captures this, so we **rank by p-value**: **most convincing first**.

## How "top" was chosen in the other outputs

| Output | How many shown | How chosen |
|---|---|---|
| **task4_top_pathways_per_group.csv** | top **10** per group per database | smallest p-value (significant only) |
| **Dot plots** | top **5** per database per group | smallest p-value |
| **Hallmark heatmap** | **all** significant (Hallmark is only 50 pathways) | q < 0.05 |
| **GO / KEGG / Reactome heatmaps** | top **5** per group, then shown across all groups | smallest p-value |
| **enrichment_tables/** folder | **every** pathway tested, significant or not | complete record |

## Note on GO
GO has many **overlapping pathways**. For example, "myeloid leukocyte activation", "myeloid cell activation" and "leukocyte activation" share many of the same genes. So the top 10 GO terms often say **the same thing in slightly different words**. Here, almost all of them are about **immune cell activation**.

When writing the paper, **group similar terms** into one theme:
> "Fibrosis-only rising genes were enriched for immune cell activation (myeloid, T cell and mast cell activation; FDR < 10⁻⁶)."

## In one sentence
> **For each gene list and each database, we kept only significant pathways (q < 0.05), sorted them by p-value (most convincing first), and took the top 10.**


---

## for each grpoup/...how amny pathways we mentioned as best

for each grpoup/...how amny pathways we mentioned as best


<sub>ran — Bash: Count top pathways listed per group and database</sub>

Here's how many **top pathways** each group has in `task4_top_pathways_per_group.csv`. The rule is **up to 10 per database**: if fewer than 10 are significant, we list only the ones that are.

## Main groups

| Group | GO | KEGG | Reactome | Hallmark | **Total** |
|---|---|---|---|---|---|
| Fibrosis-only, rising | 10 | 10 | 10 | 7 | **37** |
| Fibrosis-only, falling | 10 | 10 | 10 | 8 | **38** |
| Inflammation-only, rising | 2 | 1 | 10 | 2 | **15** |
| Inflammation-only, falling | 0 | 0 | 0 | 0 | **0** |
| Shared, rising | 10 | 10 | 10 | 10 | **40** |
| Shared, falling | 10 | 10 | 10 | 5 | **35** |
| C1 Early increase | 10 | 10 | 10 | 10 | **40** |
| C2 Late increase | 10 | 10 | 10 | 10 | **40** |
| C3 Early rise, plateau | 10 | 3 | 10 | 3 | **26** |
| C4 Mid decrease | 5 | 1 | 2 | 2 | **10** |
| C5 Late decrease | 10 | 10 | 10 | 7 | **37** |

## Check groups (high-confidence cluster genes only)

| Group | GO | KEGG | Reactome | Hallmark | **Total** |
|---|---|---|---|---|---|
| C1 core (47 genes) | 10 | 1 | 2 | 0 | **13** |
| C2 core (841 genes) | 10 | 8 | 10 | 10 | **38** |
| C3 core (36 genes) | 10 | 0 | 10 | 5 | **25** |
| C4 core (78 genes) | 0 | 0 | 1 | 0 | **1** |
| C5 core (423 genes) | 10 | 10 | 10 | 7 | **37** |

**In total: 432 top pathways across all 16 groups.**

## How to read it
- **10 means there were at least 10 significant pathways**, so we show the best 10. There may be many more; for example, shared rising has 446 significant GO terms, and all of them are in `task4_all_significant.csv`.
- **Fewer than 10 means only that many passed** q < 0.05, so we show all of them.
- **0 means no pathway was significant.**

## What stands out
- **Strong groups (35–40 pathways):** fibrosis-only, shared, C1, C2 and C5. They have a **clear biological theme**.
- **Weak groups:**
  - **Inflammation-only, falling: 0.** These 450 genes don't share any clear job.
  - **Inflammation-only, rising: 15**, mostly from Reactome. A weak signal.
  - **C4: 10**, and its core has just **1**. No clear theme.
- **Small core groups** (C1 core with 47 genes, C3 core with 36 genes): fewer genes means less power, so fewer pathways pass, especially in KEGG and Hallmark.

## In one sentence
> **We listed up to 10 best pathways per database for each group (up to 40 per group). Strong groups reached nearly 40, while inflammation-only falling and C4 had few or none, meaning those genes don't share a clear biological job.**


---

## what is this dot plots

what is this dot plots


---

## [Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-l

[Image: source: C:\Users\nissa\AppData\Local\Temp\claude\C--Users-nissa-OneDrive-Desktop-liver-kg\7f5d7c5d-fd79-4f2d-8e10-fd832edd2266\images\18.webp]

This is the dot plot for **shared falling genes**: 356 genes that go **down** with both fibrosis and inflammation. It shows **what jobs these genes do**, as one picture.

## The parts of the picture

### Each row = one pathway (one "job")
We show the **top 5 pathways from each of the 4 databases**, so **20 rows**. The **label colour** tells you which database it's from:

| Label colour | Database |
|---|---|
| 🔵 Blue | GO Biological Process |
| 🔴 Red | KEGG |
| 🟣 Purple | Reactome |
| 🟢 Green | Hallmark |

### Position left to right = gene ratio
**What share of our 356 genes belong to this pathway.**
- **Further right** means **more of our genes** do this job.
- Example: the top dot, "Small molecule catabolic process", is at **0.10**, so **10% of our 356 genes (about 36 genes)** do this job.

### Size of the dot = number of genes
**Bigger dot means more of our genes are in this pathway.** The legend in the corner shows sizes for 5, 20 and 50 genes.

### Colour of the dot = how sure we are
The colour shows **−log10 FDR**, which is just a way to show very small q-values:

| Colour | −log10 FDR | Actual FDR (q) | Meaning |
|---|---|---|---|
| 🟡 Yellow | 10 | 0.0000000001 | **extremely sure** |
| 🟢 Green | 8 | 0.00000001 | very sure |
| 🔵 Blue | 4 | 0.0001 | sure |
| 🟣 Dark purple | 2 | 0.01 | still significant |

**Brighter (yellow) means more convincing.** Every dot on this plot is significant (FDR < 0.05). Even the darkest dots passed.

**Why "−log10"?** The q-values are tiny numbers like 0.0000000001, which are hard to compare. −log10 turns them into easy numbers: 0.0000000001 → **10**. **Bigger number = smaller q = stronger evidence.**

## What this plot tells us
Look at the **best dots**, the big yellow ones in the top right:
- Small molecule **catabolic** process
- **Amino acid** metabolic process
- Organic acid **catabolic** process

**Catabolic means breaking things down.** And the other pathways:

| Theme | Pathways |
|---|---|
| 🍖 Breaking down **amino acids** | amino acid metabolism, valine/leucine/isoleucine degradation, lysine and tryptophan breakdown |
| 💊 Breaking down **drugs and toxins** | drug metabolism (cytochrome P450), xenobiotic metabolism, drug ADME |
| 🧈 Processing **fat and bile** | fatty acid metabolism, bile acid metabolism |
| 🩸 Making **clotting proteins** | coagulation |
| 🥕 Processing **vitamin A** | retinol metabolism |

**All of these are normal jobs of a healthy liver.**

## The meaning in one sentence
> **As fibrosis and inflammation get worse, the liver gradually loses its normal jobs: breaking down amino acids, drugs, fats and bile, and making clotting factors.**

This makes medical sense. Patients with advanced liver disease have trouble clearing drugs and toxins, and their **blood doesn't clot properly**.

## How to read any dot plot quickly
1. Look at the **top-right, big, yellow dots**. Those are the **strongest** results.
2. Read their names to get the **main theme**.
3. Check whether the **other dots tell the same story**. Here they all do: liver metabolism.

There's one dot plot like this for **every group**, in `Task4/dot_plots/`.


---

## those top 5 belong to liver?

those top 5 belong to liver?


<sub>ran — Bash: Show genes behind shared_down top 5 GO terms</sub>

**Two parts to the answer:**
- **The pathway names are general.** Amino-acid breakdown happens in many tissues, such as muscle and kidney.
- **The genes behind them are mostly liver genes.** To check, I looked at which of our genes made these top 5 pathways significant.

## The genes behind the top 5 GO pathways
Many genes appear in several of the top 5 (they overlap a lot). Here are the most telling ones:

| Gene | Job | Where it works |
|---|---|---|
| **ARG1** | removes toxic ammonia (urea cycle) | **liver-specific** |
| **NAGS** | starts the urea cycle | **mainly liver** |
| **PAH** | breaks down phenylalanine (the gene behind the disease PKU) | **mainly liver** |
| **MAT1A** | processes methionine | **liver-specific** (the "1A" form is the liver version) |
| **GLS2** | "liver-type" glutaminase | **mainly liver** |
| **HAL** | breaks down histidine | **mainly liver** |
| **GNMT** | controls methyl groups | **mainly liver** |
| **BAAT** | attaches amino acids to bile acids | **liver-specific** |
| **AKR1D1** | makes bile acids | **liver-specific** |
| **AGXT2, HAO2, CYP4A11** | amino acid and fat breakdown | **liver and kidney** |
| ACADSB, BCKDHB, DBT, HIBADH | break down branched-chain amino acids | many tissues, with liver a major site |

## So the answer is
> **The pathway names are general, but the genes driving them are largely genes found mainly or only in the liver.**

For example, **ARG1 and NAGS run the urea cycle**, which happens **only in the liver**. Its job is to turn toxic ammonia into urea so the body can get rid of it.

## Why this matters for the paper
This makes the finding **biologically strong**:
> As liver disease progresses, **liver-specific metabolic genes switch off**: the urea cycle (ARG1, NAGS), amino-acid breakdown (PAH, MAT1A, HAL) and bile acid production (BAAT, AKR1D1).

And it matches what doctors see in patients with advanced liver disease:
- **High blood ammonia**, because the urea cycle is failing, which can cause confusion (hepatic encephalopathy)
- **Abnormal amino acid levels** in the blood
- **Problems with bile and fat digestion**

## Tip
When you write about pathway results, **name a few key genes**, as above. It shows the result is **liver-relevant**, not just a general pathway name:
> "Shared down-regulated genes were enriched for amino acid catabolism (FDR < 10⁻¹⁰), driven by hepatocyte-specific enzymes including ARG1, NAGS, PAH and MAT1A."

You can find the genes for any pathway in the **genes** column of the enrichment tables.


---

## so those pathways are just top 5 from database

so those pathways are just top 5 from database

**Not exactly.** They're the **top 5 from the database for *our* genes**, not the database's own top 5.

## What actually happened
Each database contains **thousands of pathways**:

| Database | Pathways we tested |
|---|---|
| GO | 4,853 |
| KEGG | 183 |
| Reactome | 1,279 |
| Hallmark | 50 |

The database **doesn't have a "top 5"** of its own. It's just a big list of pathways.

**What we did:**
1. **Tested every pathway** in the database against our 356 genes.
2. Asked of each one: **do our genes appear in it more than expected by chance?**
3. **Kept only the significant ones** (q < 0.05).
4. **Ranked them** by how convincing they are (p-value).
5. **Showed the top 5** in the dot plot.

## Simple analogy
Think of the database as a **library with 5,000 books** (pathways). You have a **bag of 356 words** (our genes).

For each book, you ask: **"Does this book contain many of my words, more than you'd expect by chance?"**

Then you list the **5 books that match your words best**.

The top 5 isn't "the 5 best books in the library". It's **"the 5 books that best match MY words"**.

## So for shared falling genes
Out of **4,853 GO pathways**:
- **62 were significant**, meaning our genes are truly enriched in them.
- The dot plot shows the **5 strongest**.
- The other 57 are in `enrichment_tables/shared_down__GO_BP.csv`.

A **different gene group gets a completely different top 5**. For example, **shared rising** genes get scar formation and collagen at the top.

## In one sentence
> **We tested every pathway in each database, kept the ones our genes are significantly enriched in, and showed the 5 that match our genes most strongly. So the top 5 is decided by our data, not by the database.**


---

## so for each group we have picked top 5 pathways where our genes are mostly involved and tr

so for each group we have picked top 5 pathways where our genes are mostly involved and truely involved

**Yes, that's right.** One small correction makes it exact.

## Your sentence, slightly refined
> For each group, and **for each of the 4 databases**, we picked the **top 5 pathways** where our genes are **truly enriched** (q < 0.05) and **most convincingly** enriched (smallest p-value).

## The two parts

### ✅ "Truly involved": correct
Every pathway shown passed **FDR < 0.05**, so it's **not luck**.

### ⚠️ "Mostly involved": almost
We didn't rank by "most genes". We ranked by **most convincing** (p-value), which considers **both**:
1. **How many** of our genes are in the pathway
2. **How much more than chance** that is

So a pathway with **many genes at a moderate enrichment** can rank above one with **few genes at a high enrichment**, because it's **stronger evidence**. That's why "most convincingly" is a slightly better word than "mostly".

## How many per group
- **Dot plots:** top **5 per database** → up to **20 pathways per group** (5 GO + 5 KEGG + 5 Reactome + 5 Hallmark)
- **task4_top_pathways_per_group.csv:** top **10 per database** → up to **40 per group**
- **enrichment_tables/:** **every** pathway tested, for the full record

If a group had **fewer than 5** significant pathways in a database, we showed **only those**. For example, inflammation-only falling showed **none**.

## In one sentence
> **For each group, we showed the pathways where our genes are truly (significantly) and most convincingly enriched: the top 5 from each database.**


---

## push the entire project into github

push the entire project into github


<sub>ran — Bash: Check git status, remote, ignore rules and sizes · Bash: Check remote branches, unpushed commits, repo visibility</sub>

Before pushing, I'm checking that nothing is too big for GitHub (100 MB per-file limit) in the 9 earlier commits that were never pushed:


<sub>ran — Bash: Find large files in unpushed commits · Bash: Recount sizes of unpushed objects · Bash: Update gitignore and stage Paper 1 work · Bash: Commit Paper 1 work and push branch to GitHub</sub>

The whole project is now on GitHub, in your repository **[nissankararaoThanvitha/liver_graph](https://github.com/nissankararaoThanvitha/liver_graph)**.

**What was uploaded**
- **Your 9 earlier commits**, which had never been pushed: clinical labels, progression genes, OptimusKG, link prediction and the mentor export.
- **1 new commit with all the Paper 1 work:**
  - the 4 analysis scripts (`paper1_task1_groups.py` to `paper1_task4_enrichment.py`)
  - the full `Paper1_Results/` folder: every CSV, plot and README for Tasks 1–4

**What was left out on purpose**
- **The pathway database files** (`data/genesets/`). KEGG's licence doesn't allow sharing them. The download link is written in `.gitignore`, so anyone can get them again.
- **`Paper1_Results.zip`**, because it's just a copy of the folder.
- **The very large data folders**, which were already excluded before (over 1 GB, and they can be rebuilt).

**Where to find it**
Everything is on a branch called **`harmonize-clinical-metadata`**, not on `main`. So if you open the repository page, you'll see the old `main` version first.

To see the new work, open:
https://github.com/nissankararaoThanvitha/liver_graph/tree/harmonize-clinical-metadata

Or, on the repository page, click the **branch dropdown** (it says "main") and choose **harmonize-clinical-metadata**.

Should I also move everything onto **`main`**, so it shows on the front page? I can do that by opening a pull request (which you approve on GitHub) or by merging it directly.


---

## so everything is there in the github right

so everything is there in the github right


<sub>ran — Bash: Verify GitHub matches local project</sub>

Yes. GitHub now matches your computer exactly, apart from the files we left out on purpose.

- **Latest version:** the newest commit on your computer and on GitHub is the same one (`4011761`).
- **Nothing waiting:** there are no changes that haven't been uploaded.
- **Results folder:** all **112 files** in `Paper1_Results` are on GitHub.

**On GitHub:**
- all your code (the earlier pipeline scripts and the 4 Paper 1 scripts)
- all Paper 1 results: the CSVs, plots and READMEs for Tasks 1–4
- your full commit history
- the smaller data files that were already being tracked

**Not on GitHub, on purpose:**
- the **pathway database files**, because KEGG's licence doesn't allow sharing them. The download link is in `.gitignore`.
- the **zip file**, which is just a copy of `Paper1_Results`
- the **very large data folders** (over 1 GB). The commands to rebuild them are written in `.gitignore`.

All of it is on the **`harmonize-clinical-metadata`** branch, not `main`, so switch to that branch on the GitHub page to see it. If you'd like it to appear on `main` (the default page), tell me and I'll merge it.
